{'breast cancer': {'bisphosphonates': 1, 'denosumab': 1, 'actinomyces': 4, 'chemotherapy': 57, 'estradiol': 8, 'testosterone': 1, 'progesterone': 2, 'akt inhibitor': 1, 'paclitaxel': 8, 'foundationone': 1, 'pupose': 1, 'multitesting': 1, 'msh6': 1, 'msh2': 1, 'amino acid ( amino acid': 1, 'amino acid': 5, 'deregulation': 1, 'kaempferol': 1, 'ascorbic acid': 1, 'tamoxifen': 34, 'hydroethanolic': 2, 'nitric oxide': 1, 'malondialdehyde': 9, 'glutathione peroxidase ( gsh - px )': 1, 'trastuzumab': 14, 'heparin': 1, 'poloxamer': 1, 'curcuminoid': 2, 'cisplatin': 4, 'nanogels': 2, 'curcumin': 7, 'anticancer': 3, 'glutathione ( gsh )': 1, 'superoxide dismutase ( superoxide dismutase )': 1, 'doxorubicin': 11, 'ovulation': 1, 'letrozole': 12, 'clomiphene citrate': 3, 'clomiphene': 6, 'livebirth': 5, 'takeda': 1, 'roche': 1, 'estrogen receptor / progesterone receptor / human epidermal growth factor receptor': 1, 'fasting insulin': 2, 'insulin': 3, 'antineoplastic': 1, 'suramin': 3, 'suramin compound derivatives synthesized herein show potential as novel therapeutic agents for their anti - proliferative activity via': 1, 'suramin compound': 1, 'ursolic acid ( ursolic acid': 1, 'ursolic acid': 6, 'artemisinin': 1, 'dihydroartemisinin': 3, 'neoadjuvant chemotherapy': 8, 'parp inhibitor': 1, 'parp inhibitors': 1, 'tumourectomy': 1, 'hormonotherapy': 1, 'compound kushen': 2, 'chemotherapies': 1, 'nomogram': 1, 'crispr': 2, 'progesterone receptor (pr ( progesterone receptor )': 2, 'estrogen receptor': 3, 'herceptin': 14, 'dimerization blocker , stattic ( s )': 1, 'nanocarrier': 1, 'stattic': 5, 'plga nanoparticles': 1, "progesterone receptor (pr status . rates of high wilms' tumor 1-associated protein expression were 66.1": 1, 'abemaciclib': 3, 'steroid': 2, 'prednisolone': 2, 'progesterone receptor': 1, 'eribulin': 1, 'fulvestrant': 3, 'ec': 1, 'capecitabine': 1, 'docetaxel': 4, 'nivolumab': 3, 'anastrozole': 2, 'epirubicin': 5, 'cyclophosphamide': 6, 'fructose': 1, 'pertuzumab': 5, 'fluorouracil': 7, 'neosphere': 1, 'tryphaena': 1, 'imatinib': 4, 'cholesterol biosynthesis': 1, 'epoxidase inhibitors': 1, 'antifungal': 1, 'chemotherapy(tc)and': 1, 'chemo': 2, 'bevacizumab': 4, 'fulvestrant)was': 1, 'gemcitabine': 1, 'nab - paclitaxel': 1, 'icg': 1, 'intratumorally': 1, 'photodynamic': 1, 'aromatase inhibitors': 1, 'cdk4/6 inhibitors': 1, 'glucocorticoid': 1, 'anthracycline': 1, 'progesterone receptor (pr membrane component': 1, 'progesterone receptor membrane component': 7, 'fpr2': 1, 'gpr37': 1, 'ccr5': 1, 'radioactive iodine ( radioactive iodine ) treatment increased markedly . radioactive iodine': 1, 'radioactive iodine treatment': 2, 'radioactive iodine ( yes v no or unknown ) using poisson regression among > /= 5-': 1, 'radioactive iodine treatment ( 45': 1, 'nonsignificantly': 1, 'radioactive iodine': 2, 'carboplatin': 3, 'blebbing': 1, 'psychotropics': 1, 'doxycycline': 1, 'citrate ions': 1, 'anticancer compounds': 1, 'psn': 1, 'cancer': 1, 'progesterone receptor ) receptor (pr - negative human breast cancer (bc . here , we show that reverting the high lip': 1, 'nmyc': 1, 'psycinfo': 1, 'hormone binding globulin ( sex hormone binding globulin )': 1, 'hormone binding globulin': 1, 'hormone binding globulin by suppression status . conclusions : there were no differences in fe2 but significantly lower e2 and higher sex hormone binding globulin among women with hiv versus without hiv . further research is merited in a large contemporary sample': 1, 'adjuvant': 1, 'bisphosphonate': 6, 'ibandronate': 1, 'zoledronic acid': 1, 'glutathione peroxidase': 2, 'irgd': 1, 'ferroptosis': 1, 'postmastectomy': 1, 'clinicopathological': 1, 'progesterone receptor (pr ( pgr ) status , in which er-/pgr + tended to present the worst prognosis . conclusion : this study revealed profound heterogeneity associated with hazard ratios status in the clinical outcomes of human epidermal growth factor receptor 2 - positive breast cancer (bc regarding clinicopathological': 1, 'ado - trastuzumab emtansine ( t - dm1 )': 1, 'monoclonal antibody': 1, 'microtubule inhibitor emtansine': 1, 'l1cam': 1, 'shrna': 1, 'oncomine': 1, 'aurein': 1, 'aromatase inhibitors ( aromatase inhibitors )': 1, 'nsaids': 1, '2012.purpose': 1, '12,907': 1, 'chop': 1, 'pampk': 2, 'grp78': 2, 'bax': 2, 'valrubicin': 1, 'antibiotics': 1, 'steroids': 2, 'leuprorelin': 1}, 'tumor': {'folfirinox': 1, 'immunoglobulin': 1, 'methylprednisolone': 1, 'somatostatin': 1, 'bisphosphonates': 1, 'denosumab': 1, 'actinomyces': 4, 'chemotherapy': 36, 'rapamycin': 5, 'pancreaticoduodenectomy': 2, 'linifanib': 1, 'hdac': 1, 'chemo': 1, 'interleukin-2': 61, 'il-2': 56, 'docetaxel': 5, 'gemcitabine': 1, 'nab - paclitaxel against b16f10': 1, 'covalent inhibitor': 1, 'gsh': 1, 'astragalus polysaccharides': 1, 'astragalus polysaccharides )': 1, 'catla': 2, 'catla catla )': 1, 'albumin': 1, 'malondialdehyde': 1, 'glutathione peroxidase ( glutathione peroxidase': 1, 'nitric oxide synthase ( nitric oxide synthase )': 1, 'hydrogen peroxides ( h2o2 )': 1, 'astragalus polysaccharides diets on week': 1, 'astragalus polysaccharides enriched diets revealed significant improved tumor necrosis factor ( tnf)-alpha and tumor necrosis factor receptor - associated factor-6 ( tnf receptor-associated factor-6 ) mrna expression on week': 1, 'paclitaxel': 6, 'praziquantel': 1, 'pd-1': 1, 'pemetrexed': 1, 'cisplatin': 5, 'mek inhibitor ( mek inhibitor': 1, 'mek inhibitor / anti - pancreaticoduodenectomy - l1 therapy (pdt': 1, 'optn': 1, 'photothermal': 6, 'aecii': 1, 'spirulina': 2, 'atezolizumab': 1, 'akt inhibitor': 1, 'foundationone': 1, 'taxane': 2, 'cobas': 1, 'osimertinib': 1, 'fluorouracil': 1, 'leucovorin': 1, 'irinotecan': 8, 'oxaliplatin': 1, 'serine hydrolase carboxylesterase': 1, 'pdgfra': 1, 'nctn': 1, 'amino acid ( amino acid': 1, 'amino acid': 5, 'o2': 1, 'mineral nanomedicine': 1, 'europium - doped calcium fluoride': 1, 'electrodynamic': 2, 'zeolite imidazole': 1, 'single amino acid mutations': 1, 'mmp8': 1, 'eotaxin': 1, 'tgfrbeta': 1, 'mmp2': 1, 'phosphodiesterase-5 inhibitors': 1, 'metformin': 11, 'neoadjuvant immunotherapy': 1, 'nivolumab': 1, 'ipilimumab': 2, 'pembrolizumab': 5, 'beta - hydroxybutyrate ( beta-hydroxybutyrate )': 1, 'fatty acid': 4, 'insulin': 3, 'beta-hydroxybutyrate': 1, 'quantitative insulin sensitivity check index rquicki - beta-hydroxybutyrate': 1, 'suvmean': 1, 'kaempferol': 1, 'ascorbic acid': 1, 'fatty acids': 1, 'hexadecenoic acid': 1, 'il-2 hydroxy octadecanoic acid': 1, 'dienes': 1, 'phytosphingosine': 1, 'doxorubicin': 3, 'ceramide b ( 2 )': 2, 'sertoliomas': 1, 'aprepitant': 1, 'clinicopathological': 2, 'heparin': 1, 'poloxamer': 1, 'curcuminoid': 2, 'nanogels': 2, 'curcumin': 2, 'annexin': 1, 'p38 inhibitor': 1, 'jnk inhibitor': 1, 'pklr': 1, 'furosemide': 3, 'cimetidine': 2, 'para - amino hippuric acid': 1, 'saline': 1, 'oat inhibitor': 1, 'superoxide dismutase': 1, 'lavage': 3, 'conatumumab': 1, 'quercetin': 1, 'glucocorticoid receptor interactions in normal tissues and tumor is crucial': 1, 'glucocorticoid receptor antagonists ru486 ( mifepristone )': 1, 'dexamethasone': 1, 'antagonist': 1, 'glucocorticoid receptor interactions can be measured in vivo with (': 1, 'glucocorticoid receptor antagonists': 1, 'c5ar antagonist blocked': 1, 'ductal': 2, 'acinar': 1, 'clonally': 1, 'uracil': 1, 'cytarabine': 1, "1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide ( 1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide )": 1, "1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide": 1, 'mir-133b': 7, 'wilcoxon': 1, 'shrewd immunohistochemical': 1, 'anisole': 1, 'receptor alpha immunohistochemical expression .': 1, 'receptor alpha immunohistochemical expression , respectively . thus , enhancer of zeste homolog 2': 1, 'tfeb': 2, 'intratumoral': 1, 'beta receptor (': 1, 'beta receptor )': 1, 'beta receptor in': 1, 'beta receptor': 1, 'lymphotoxin': 1, 'beta receptor activated the non - canonical nf - kappab signaling pathway in nih3t3 cells': 1, 'lymphotoxin-beta receptor - nih3t3 cells': 1, 'beta receptor - nih3t3 cells': 1, 'lumbosacral': 1, 'lactic acid bacteria ( lactic acid bacteria )': 1, 'lactic acid bacteria': 1, 'streptozotocin': 4, 'curcumin nanoparticles ( curcumin nanoparticles': 1, 'nitric oxide ( nitric oxide': 1, 'curcumin nanoparticles': 1, 'immunoblotting': 1, 'sorafenib': 9, 'lenvatinib': 6}, 'cancer': {'urapidil': 1, 'bisphosphonates': 1, 'denosumab': 1, 'actinomyces': 4, 'chemotherapy': 44, 'intratumoral': 1, 'corynoline': 1, 'acetylcorynoline': 2, 'rapamycin': 4, 'mercapturic acid': 1, 'multivalency': 1, 'linifanib': 1, 'cytosponge': 1, 'rosetrees': 1, 'stoneygate': 1, 'cisplatin': 11, 'gemcitabine': 9, 'pemetrexed': 2, 'bevacizumab': 4, 'demethylase': 6, 'higenamine': 1, 'hdac': 1, 'magl': 1, 'pharmacokinetics': 1, 'chemoradiotherapy': 4, 'carboplatin': 5, 'paclitaxel': 11, 'trametinib': 2, '-1/1/2/3': 1, 'pd-1 monoclonal antibody treatment . collectively , these data demonstrate that ifitm4p may serve as a new therapeutic target in blockage of oral': 1, 'pd-1 monoclonal antibody can be an efective reagent': 1, 'chemo': 1, 'docetaxel': 5, 'nab - paclitaxel against b16f10': 1, 'paeoniaceae': 1, 'p70s6 k signaling': 1, 'imidazoquinoline agonists': 1, 'covalent inhibitor': 1, 'gsh': 1, 'cytotoxic': 1, 'photothermal': 5, 'iron oxide': 1, 'chemotherapies': 1, 'chloroisopropyl': 2, 'phosphate': 1, 'organophosphate': 1, 'mek inhibitor ( mek inhibitor': 1, 'mek inhibitor / anti - pd - l1 therapy (pdt': 1, 'optn': 1, 'chemokine ligand': 1, 'lr': 1, 'rbc folate': 3, 'rbc': 1, 'rbc folate concentration': 1, 'normal folate status is important for reducing the risk of cervical intraepithelial': 1, 'propofol': 4, 'sevoflurane': 2, 'anesthesia': 1, 'icnb': 3, 'asa': 1, 'anesthetics': 1, 'estradiol': 1, 'testosterone': 1, 'progesterone': 1, 'nicotine': 2, 'imatinib': 3, 'erlotinib': 1, 'nilotinib': 1, 'dasatinib': 3, 'sorafenib': 1, 'scopolamine': 1, 'allyl isothiocyanate ( allyl isothiocyanate )': 1, 'allyl isothiocyanate': 4, 'allyl isothiocyanate action': 1, 'intragastrically': 1, 'irrespectively': 1, 'allyl isothiocyanate considerably lowered thyroid hormones ( ft4 , ft3 )': 1, 'allyl isothiocyanate at': 2, 'hydroxybutyric acid': 1, 'insulin': 1, 'blood insulin': 1, 'atezolizumab': 1, 'nomogram': 1, 'akt inhibitor': 1, 'foundationone': 1, 'taxane': 2, 'cobas': 1, 'osimertinib': 1, 'pupose': 1, 'multitesting': 1, 'msh6': 1, 'msh2': 1, 'nctn': 1, 'amino acid ( amino acid': 1, 'amino acid': 1, 'anticoagulation': 1, 'glyco disulfide acted as reducing and capping agents of gold ions': 1, 'o2': 1, 'crispr': 1, 'phosphodiesterase-5 inhibitors': 1, 'metformin': 11, 'lewis acid as additive': 1, 'trifluridine': 2, 'tipiracil': 2, 'ftd': 1, 'fluorouracil': 2, 'deregulation': 1, 'oxaliplatin': 3, 'supplementation': 1, 'ceramides': 1, 'fdi': 1, 'neoadjuvant immunotherapy': 1, 'nivolumab': 4, 'ipilimumab': 2, 'ccrt': 1, 'iqr': 2, 'pembrolizumab': 5, 'lignans': 1, 'adenosine triphosphate': 2, 'linalool oxide': 1, 'fatty acid biosynthesis': 1, 'phosphatidic acid': 1, 'cholesteryl esters distinguished amino acid': 1, 'suvmean': 1, 'flavonoids chemical': 1, 'superoxide anion radicals': 1, 'arthrocnemum indicum (willd.) moq. indicum shoot ethanolic extract': 1, 'kaempferol': 1, 'ascorbic acid': 1, 'isavuconazole': 6, 'mucormycosis': 1, 'antifungal': 2, 'corticosteroids': 1, 'tamoxifen': 16, 'hydroethanolic': 2, 'nitric oxide': 1, 'malondialdehyde': 1, 'glutathione peroxidase ( gsh - px )': 1, 'indole alkaloids': 1, 'diketopiperazines': 1, 'characella': 1, 'gnps': 1, 'cyanocobalamin': 1, 'vitamin b12': 1, 'undaria': 1, 'lerdsin': 1, 'mirtazapine': 7, 'chemoradiation': 1, 'niraparib': 2, 'haematological': 1, 'trastuzumab': 3, 'pd-1': 5, 'pd-1 inhibitors in combination': 1, 'pd-1 inhibitor': 1, 'adjuvant chemotherapy': 1, 'neoadjuvant chemotherapy': 1, 'irinotecan': 1, 'akaike': 1, 'alectinib': 2, 'cbdca': 3}, 'polycystic ovarian syndrome': {'letrozole': 34, 'clomiphene citrate': 7, 'clomiphene': 34, 'livebirth': 5, 'takeda': 1, 'roche': 1, 'folic acid': 1, 'folic acid (pfhxs , and a control group ( group 3': 1, 'folic acid (pfhxs from 1 month': 1, 'insulin': 96, 'impaired insulin secretion': 1, 'metformin': 67, 'normal saline water ( 0.9': 1, 'malondialdehyde': 7, 'choline': 3, 'omega-3': 2, 'omega-3 ( 10.78 + /- 1.71 )': 1, 'estradiol': 17, 'progesterone': 18, 'gpx3': 1, 'tamoxifen': 3, 'glucose': 5, 'ellagic acid treatment restored them to levels seen in the control group . ellagic acid reduced the days': 1, 'dehydroepiandrosterone': 5, 'estrogen receptor (lhr ( estrogen receptor )': 1, 'ellagic acid treatment': 1, 'ellagic acid improved glucose intolerance and insulin intolerance': 1, 'ellagic acid groups': 1, 'ellagic acid': 4, 'carbamazepine': 1, 'ovarian insulin resistance in polycystic ovarian syndrome remain elusive . methods : follicular fluid': 1, 'vitamin d': 7, 'antimullerian hormone (fsh levels , antral follicle': 1, 'luteinizing hormone (fsh / choriogonadotropin receptor (lhr ; cyp17a1 : cytochrome p450 family 17 subfamily a member': 1, 'fasting insulin ( fins : wmd -3.40': 1, 'lithium': 4, 'steroid hormone (fsh profiles were compared between patients with and without follicle-stimulating hormone receptor - autoantibodies or luteinizing hormone receptor - autoantibodies . signal linearity and detection ranges were characterized and both methods': 1, 'steroid': 9, 'scopus': 2, 'embase': 2, 'lkb1': 1, 'rapamycin': 11, 'ventriculo': 1, 'superoxide dismutase ( superoxide dismutase )': 2, 'papash': 1, 'gsh': 1, 'cinahl': 2, 'amino acid (pfhxs residues crucial': 1, 'shrna': 1, 'aspirin': 2, 'nonsteroidal': 1, 'hyperandrogenism': 3, 'sildenafil': 1, 'diuretics': 1, 'diuretic': 1, 'anorexigenic': 1, 'serum insulin': 5, 'steroidal hormones': 1, 'luteinizing hormone': 3, 'anethum': 1, 'kurz': 1, 'tilatailam': 3, 'gonadotropins': 2, 'clomiphene citrate ( clomiphene citrate': 2, 'fibroscan': 1, 'fasting insulin': 2, 'acetylcysteine': 1, 'antioxidants': 1, 'cv-6': 1, 'sp-6': 1, 'body insulin sensitivity measured by the clamp': 1, 'chemerin': 4, 'normal progesterone secretion with lower concentrations in polycystic ovarian syndrome human luteinised granulosa cells': 1, 'unani': 1, 'lashansky': 1, 'sportdiscus': 1, 'rat': 1, 'sf': 4, 'aromatase inhibitors ( aromatase inhibitors )': 1, 'aromatase inhibitors': 3, 'aromatase inhibitors treatment . polycystic ovary syndrome ( polycystic ovarian syndrome )': 1, 'chemotherapy': 3, 'herbicides': 1, 'oestrogen': 1, 'masashi': 1, 'curcumin': 6, 'oogenesis': 1, 'intracytoplasmic sperm injection': 1, 'kisspeptin hormone (fsh - release kinetics . it highlighted the recently identified ligands': 1, 'pioglitazone': 1, 'nitric oxide': 3, 'dehydroepiandrosterone - sulfate': 1, 'vitamin d supplementation': 1, 'perfluorooctanesulfonic acid )': 1, 'perfluorohexane sulfonic acid': 2, 'genistein': 6, 'estrogen receptor': 1, 'exaggerated insulin': 1, 'progesterone metabolite allopregnanolone ( allopregnanolone )': 1, 'benzodiazepines': 1, 'sepranolone': 1, 'probiotics': 2, 'synbiotics': 1, 'parasitome': 1, 'ellagic acid (pfhxs ( ellagic acid )': 1, 'cholesterol': 1, 'ellagic acid ( p < 0.05 )': 1, 'ellagic acid supplementation can be helpful as a diet supplement in women with polycystic ovarian syndrome through improvement in insulin resistance': 1, 'statin': 1, 'blood glucose': 1, 'statins': 1, 'acarbose': 1, 'myoinositol': 1, 'aucglucagon': 1, 'valproate': 3, 'lamotrigine': 6, 'ld)-vpa': 1, 'tpa': 1, 'spironolactone': 5, 'f1 formulation': 1, 'flotillin': 5, 'starbase': 1, 'hormone replacement cycles protocols ( 86': 1, 'hormone replacement cycles protocols . subsequent multivariate logistic regression analysis also yielded similar results . conclusion : stimulated cycles': 1, 'hormone replacement cycles protocols . evidence is available': 1, 'hormone replacement cycles': 1, 'gnrh receptor autoantibody': 3, 'gnrh receptor autoantibody activity in polycystic ovarian syndrome patients compared with control subjects ; and 2 ) effectiveness of gonadotrophin-releasing hormone antagonist in suppressing gnrh receptor autoantibody': 1, 'gnrh receptor autoantibody activity levels in the polycystic ovarian syndrome group were significantly higher than in the control group . with cetrorelix': 1, 'mrnas': 3, 'atropine': 1, 'theophylline': 2, 'azithromycin': 1, 'dexamethasone': 1, 'melatonin': 2, 'leptin': 2, 'insulin receptor (lhr ( insulin receptor )': 1, 'uterine insulin receptor': 1, 'testosterone': 2, 'chenodeoxycholic acid (pfhxs ( chenodeoxycholic acid )': 1, 'antibiotic': 1, 'chenodeoxycholic acid treatment': 1, 'chenodeoxycholic acid improved glucose metabolism': 1, 'skbz': 1, 'wilcoxon': 1, 'aromatase inhibitor': 1, 'venepuncture': 1, 'col6a5': 1, 'contraceptives': 1, 'lipid profle': 1, 'indonesia': 1, 'vitex': 9, 'homeopathic medicines': 1, 'fasting insulin ( r = -0.324 , p <': 1, 'free testosterone': 1, 'dehydroepiandrosterone sulfate': 1, 'vitamin c': 3, 'androgen receptor extract': 1, 'androgen receptor with vitamin c': 1, 'glutathione': 1, 'adipocytokines': 1, 'single nucleotide polymorphisms ( single nucleotide polymorphisms )': 1, 'adiponectin': 1}, 'tumors': {'somatostatin': 1, 'epoetin alpha ( retacrit(r ) )': 1, 'chemotherapy': 35, 'iron': 3, 'epoetin': 1, 'epoetin alpha biosimilar were reported': 1, 'intratumoral': 2, 'antibiotics': 1, 'diuretics': 1, 'cisplatin': 8, 'biotherapeutic cocktail': 1, 'hdac': 1, 'chemo': 6, 'docetaxel': 2, 'gemcitabine': 2, 'nab - paclitaxel against b16f10': 1, 'photothermal': 6, 'icnb': 3, 'asa': 1, 'anesthetics': 2, 'nomogram': 1, 'akt inhibitor': 1, 'paclitaxel': 16, 'foundationone': 1, 'pdgfra': 1, 'pfs': 3, 'amino acid ( amino acid': 1, 'amino acid': 3, 'o2': 1, 'phosphodiesterase-5 inhibitors': 1, 'trifluridine': 2, 'tipiracil': 2, 'ftd': 1, 'fluorouracil': 2, 'pembrolizumab': 7, 'ipilimumab': 1, 'phosphatidic acid': 1, 'cholesteryl esters distinguished amino acid': 1, 'sertoliomas': 1, 'chemoradiation': 1, 'aprepitant': 1, 'biocompatible iron oxide nanoparticle': 1, 'iron oxide': 2, 'iron oxide nanomaterials': 1, 'furosemide': 3, 'cimetidine': 2, 'para - amino hippuric acid': 1, 'saline': 1, 'oat inhibitor': 1, 'carboplatin': 2, 'albumin': 1, 'isoniazid': 1, 'rifampin': 1, 'premetrexed': 1, 'ductal': 2, 'acinar': 1, 'clonally': 1, 'overexpressing': 1, 'uracil': 1, 'doxorubicin': 8, 'cytarabine': 1, "1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide ( 1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide )": 1, "1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide": 1, 'oxaliplatin': 8, 'liposomal oxaliplatin': 1, 'shrewd immunohistochemical': 1, 'anisole': 1, 'tfeb': 3, 'alizarin red stainings': 1, 'osteopontin': 1, 'myomatous': 1, '95%ci': 1, 'intracytoplasmic': 1, 'vacuolation': 1, 'taxol': 3, 'taxane': 1, 'kirsten rat sarcoma viral oncogene proto - oncogene gtpase ( kirsten rat sarcoma viral oncogene )': 1, 'ameloblastomas': 2, 'unerupted': 2, 'steroid hormone biosynthesis , bile acid biosynthesis': 1, 'estrogen biosynthesis': 1, 'heterotypic': 1, 'palisading': 1, 'histopathological': 1, 'crispr': 1, 'tetracycline': 1, 'doxycycline': 1, 'cox-2': 1, 'microsomal prostaglandin e': 1, 'ptges': 3, 'azoxymethane': 1, 'dextran sodium sulfate': 1, 'mpges-1': 2, 'methylprednisolone': 1, 'steroids': 1, 'immunosuppressants': 1, 'purine nucleoside monophosphate metabolic process': 1, 'interferon genes agonists': 1, 'antagonists': 1, 'anesthesia': 3, 'cnki': 1, 'wanfang': 1, 'chemoradiotherapy': 1, 'sox': 2, 'bevacizumab': 3, 'iris': 1, 'imatinib': 5, 'trastuzumab': 2, 'ramucirumab': 1, 'nivolumab': 2, 'irinotecan': 1, 'steroid': 2, 'gammadelta t cells': 1, 'vip152': 1, 'somatostatin analogs ( somatostatin analogs': 1, 'radiolabeled somatostatin analogs': 1, 'capecitabine': 1, 'nab - paclitaxel plus ramucirumab . the tumor marker levels decreased , the lymph nodes shrank , and pr': 1, 'erythropoietin': 1}, 'gastric cancer': {'clinicopathological': 1, 'chemotherapy': 87, 'paclitaxel': 11, 'antifungal': 1, 'anticancer': 2, 'brd4': 1, 'oxaliplatin': 45, 'nivolumab': 20, 'unresectable': 4, 'steroid': 4, 'adachi': 3, 'docetaxel': 24, 'trastuzumab': 4, 'ramucirumab': 2, 'irinotecan': 1, 'capecitabine': 3, 'cisplatin': 3, 'ventriculoperitoneal': 1, 'nab - paclitaxel': 1, 'peptidyl arginine deiminase': 1, 'adjuvant chemotherapy': 1, 'trastuzumab(tmab)and': 1, 'tmab': 1, 'chemotherapy(tc)and': 1, 'chemo': 2, 'anastrozole': 1, 'bevacizumab': 1, 'fulvestrant)was': 1, 'response(cr)after': 1, 'nab - paclitaxel plus ramucirumab . the tumor marker levels decreased , the lymph nodes shrank , and pathological response was achieved again with the fourth - line treatment . the treatment is still ongoing 2 year and 8 months': 1, 'iron': 1, 'erythropoietin': 1, 'folfox': 3, 'azithromycin': 1, 'oxygen': 1, 'nab - paclitaxel plus ramucirumab , then treated with nivolumab': 1, 'fluorouracil': 20, 'leucovorin': 19, 'lcv': 1, 'histone deacetylase': 3, 'antiemetic': 3, 'doxorubicin': 4, 'cyclophosphamide': 1, 'aprepitant': 1, 'tricarboxylic acid': 1, 'dexamethasone': 1, 'ahcy': 1, 'chdh': 1, 'antimitotic chemotherapy medication': 1, 'labeled docetaxel': 1, 'alvotere': 4, 'nanoalvand': 1, 'anthracyclines': 1, 'chemotherapeutic': 2, 'mir-96': 1, 'immunoblotting': 1, 'h3 lysine 4': 1, 'h3 lysine': 1, 'actinobacteria': 1, 'leptotrichia': 1, 'lachnospiraceae': 1, 'megasphaera': 1, 'f16': 1, 'moryella': 1, 'filifactor': 1, 'deregulation': 1, 'antibiotic': 4, 'clarithromycin': 1, 'metronidazole': 1, 'levofloxacin': 1, 'amoxicillin': 1, 'hsa': 1, 'podoplanin': 1, 'circrna': 1, 'mir-637': 1, 'pepsinogen': 1, 'tff1': 1, 'lbc mkn45 cells': 1, 'amino acid residues in the saccharide primers': 1, 'amino acid selectivity': 1, 'apatinib': 1, 'pembrolizumab': 3, 'polyethylene glycol - poly(epsilon - caprolactone ) ( peg - pcl ) nanoparticles ( nanoparticles )': 1, 'alvoxal': 2, 'immunohistochemistry': 1, 'preoperative': 1, 'euro22': 1, 'lactulose': 1, 'fresh frozen plasma': 1, 'hemodiafiltration': 1, 'proquest': 1, 'probiotics': 1, 'antibiotics': 3, 'asa': 2, 'cochrane library databases': 1, 'extraction': 1, 'sargassum': 1, 'senescore': 4, 'immunotherapeutic': 1, 'aspirin': 6, 'metachronous': 1, 'deacetylase inhibitors entinostat': 1, 'pracinostat': 2, 'mocetinostat': 2, 'vorinostat': 1, 'deacetylase inhibitors': 1, 'neoantigens': 3, 'neoepitope': 1, 'sphingolipid': 2, 'autophagy inhibitor': 1, 'chloroquine': 1, 'endocytosis inhibitors chlorpromazine': 1, 'sphingosine kinase 1 inhibitor': 1, 'metformin': 6, 'biguanide': 1, 'gastriccell': 1, 'vitamin b12': 1, 'vitamin b12 capsule': 5, 'celecoxib': 4, 'embase': 1, 'cnki': 1, 'nomogram': 1, 'ogdh': 1, 'citric acid': 1, 'blautia': 1, 'bifidobacterium': 1, 'butyricicoccus': 1, 'fibronectin': 1, 'azaadenosine': 1, 'famce': 1, 'copper oxide nanoparticles': 6, 'glutamic acid ( copper oxide nanoparticles': 1, 'glutamic acid )': 1, 'conjugated with thiosemicarbazone ( copper oxide nanoparticles': 1, 'glutamic acid / tsc nanoparticles': 2, 'glutamic acid nanoparticles': 1, 'glutamic acid / tsc nanoparticles efficiently inhibited the proliferation of ags cells': 1, 'glutamic acid / tsc treated cells': 1, 'glutamic acid / tsc as an efficient anticancer against gastric cancer (lbc cells': 1}, 'cardiotoxicity': {'anthracyclines': 12, 'paclitaxel': 2, 'cisplatin': 9, 'amidinourea': 2, 'r - chop regimen of pegylated liposomal': 1, 'doxorubicin': 247, 'chemotherapy': 58, 'resveratrol ( resveratrol )': 1, 'resveratrol': 3, 'antibiotic': 3, 'steroid': 2, 'diuretics': 2, 'azacitidine': 1, 'osimertinib': 4, 'oxygen': 1, 'pyroptosis': 2, 'nigericin': 2, 'calycosin': 1, 'antipyroptotic': 1, 'adenosine triphosphate': 3, 'superoxide dismutase': 2, 'anthracycline': 32, 'phthalate': 2, 'acyl hydrazine': 1, 'thiourea': 1, 'humanized monoclonal antibody': 1, 'nanoforms': 1, 'loperamide': 5, 'opioid': 3, 'methadone': 1, 'naloxone': 1, 'trastuzumab': 69, 'carboplatin': 1, 'oxaliplatin': 1, 'anticancer': 8, 'bortezomib': 6, 'normal saline': 1, 'receptor agonist': 1, 'bupivacaine': 3, 'bw373u86': 1, 'pegylated': 2, 'adriamycin': 2, 'isoproterenol': 5, 's.c': 1, 'anesthesia': 1, 'tamoxifen': 3, 'paroxetine': 3, 'lapatinib': 4, 'bcl': 1, 'cyclophosphamide': 4, 'chrysin': 1, 'malondialdehyde': 22, 'acetylcholinesterase': 6, 'chemotherapies': 1, 'imatinib': 3, 'ponatinib': 2, 'transporter inhibitors in different cell lines': 1, 'il-2': 1, 'ifngamma': 1, 'immunomodulatory monoclonal antibodies endowed with more potent anti - cancer activity on triple negative breast cancer and lower cardiotoxic side effects than the combination of atezolizumab': 1, 'ipilimumab': 4, 'fondazione italiana linfomi )': 1, 'liposomal': 1, 'doxorubicine': 1, 'reinduction': 1, 'clofarabine': 1, 'vinorelbine': 1, 'thiotepa': 1, 'loulu': 3, 'gapdh': 1, 'nicotinamide': 1, 'coumarin': 1, 'parthenolide': 1, 'ligustilide': 1, 'aihf': 2, 'arenobufagin': 9, 'analgesic': 2, 'free radicals': 1, 'dawley': 1, 'hyaluronate': 1, 'nanocarrier': 1, 'hyaluronic acid ( hyaluronic acid )': 1, 'solanesol': 1, 'hyaluronic acid': 2, 'conjugate ( hyaluronic acid - solanesyl thiosalicylate )': 1, 'hyaluronic acid - solanesyl thiosalicylate nanoparticles': 1, 'hyaluronic acid - solanesyl thiosalicylate - doxorubicin showed superior tumor inhibition compared with free doxorubicin , as well as lower cardiotoxicity and': 1, 'rvlpulse': 1, 'zebralab': 1, 'ticlopidine': 9, 'adp': 4, 'adenosine diphosphate': 1, 'astragali': 3, 'dantrolene': 6, 'calcium': 1, 'fluorouracil': 1, 'valsartan': 2, 'amlodipine': 2, 'lisinopril': 3, 'rats': 1, 'lsp': 1, 'pretreatments': 1, 'mitoxantrone': 8, 'glutathione peroxidase ( gsh - px )': 2, 'subchronic': 1, 'mtx': 12, 'disulfiram': 2, 'humanized monoclonal antibody that significantly improves metastatic and non - metastatic breast cancer therapeutic outcomes . this study compares': 1, 'crocin': 3, 'milrinone': 1, 'iii inhibitor in cynomolgus monkeys , and share': 1, 'interactions': 1, 'pd-1': 1, 'prevotellaceae': 1, 'butyrate supplementation alleviated pd-1 / pd - l1 inhibitor': 1, 'chemo': 2, 'oseltamivir': 3, 'epirubicin': 6, 'daunorubicin': 1, 'imatinib mesylate ( imatinib mesylate': 1, 'imatinib mesylate': 4, 'imatinib mesylate - treated groups . oil red o staining suggested obvious cardiac lipid accumulation after': 1, 'monoclonal antibodies': 1, 'pertuzumab': 1, 'fenitrothion': 8, 'glutathione reductase ( glutathione reductase )': 1, 'superoxide dismutase ( superoxide dismutase )': 2, 'resveratrol complexes with protein and dna sequences of sirt1 were lower than docked complexes': 1, 'neoadjuvant chemotherapy': 3, 'mangostin': 3, 'vitamin e ( 200 iu / kg )': 1, 'vitamin e ( 19 days )': 1, 'intraperitoneally': 1, 'antiinflammatory': 1, 'antiapoptotic': 1, 'catecholaminergic hormone release': 1, 'free': 1, 'dioscorea': 1, 'methotrexate': 2, 'troxerutin': 2, 'ampk': 1, 'superoxide dismutase antioxidants': 1, 'angiotensin receptor blockers (arbs ( angiotensin receptor blockers )': 1, 'beta-blockers and angiotensin-converting enzyme inhibitors / angiotensin receptor blockers': 1, 'bb': 3, 'angiotensin': 1, 'beta-blockers or angiotensin-converting enzyme inhibitors / angiotensin receptor blockers were significantly associated with higher lvefs . for anthracyclines': 1, 'quercetin ( quercetin )': 1, 'quercetin': 1, 'monotherapy': 1, 'nivolumab': 3, 'pembrolizumab': 3, 'n=39': 1, 'arachidonic acid metabolism , linoleic acid metabolism': 1, 'dox': 2, 'mercapturic acid pathway enzyme': 1, 'omega-6': 1, 'rlip': 2, 'arachidonic acid': 3, 'antineoplastic': 1, 'her2 inhibitors': 1, 'arachidonic acid increased lipid peroxidation': 1, 'rlip inhibitors': 1, 'zm447439': 1, 'hdac inhibitor': 1, 'regular blood transfusion': 1, 'iron': 1, 'antiseizure medications ( antiseizure medications': 1, 'antiseizure medications': 1, 'antiseizure medications should be considered ; cardiac monitoring of treatment': 1, 'embase': 2, 'cinahl': 1, 'carfilzomib': 3, 'proteasome inhibitor': 1, 'chalcone': 2, 'ciprofloxacino': 1, 'ethidium bromide': 1, 'coenzyme q10': 1, 'histopathological': 3, 'ultrastructurally': 1, 'corticosteroids': 2, 'corticosteroid': 15, 'tofacitinib': 1, 'herceptin': 7, 'ferroptosis inhibitor': 1, 'deferoxamine': 1, 'dcfhdaa': 1, 'timedependent': 2, 'glutathione peroxidase ( glutathione peroxidase ) protein expression and the gsh/ gssg ratio in h9c2 cells (wbc in a dose': 1, 'mitofusin': 1, 'selenium plays crucial roles in maintaining the growth and development of vertebrates': 1, 'selenium': 1, 'human': 1, 'synthetic opioids': 1, 'morphine': 1, 'gsh': 2, 'interleukin': 2, 'vegfr': 1, 'bevacizumab': 1, 'immunomodulation': 1, 'sodium chloride solution': 1, 'nicotinic receptor agonist ( pnu : pnu-282987': 1, 'muscarinic receptor agonist ( bet : bethanechol ,': 1, 'alpha7nachr': 2, 'acetylcholine receptors agonists protected': 1, 'caffeic acid phenethyl ester ( caffeic acid phenethyl ester )': 1, 'caffeic acid phenethyl ester': 2, 'caffeic acid phenethyl ester significantly ameliorated': 1, 'mechanistically': 1, 'caffeic acid phenethyl ester attenuated the': 1, 'caffeic acid phenethyl ester significantly enhanced': 1, 'benzofuran': 1, 'chemotypes': 1, 'megestrol': 1, 'megestrol acetate': 1, 'fatty acid oxidation': 1, 'grp78': 1, 'adenosine triphosphate ( adenosine triphosphate )': 1, 'cardiotoxicity': 1, 'radiodensity': 1, 'asparaginase': 1, 'perindopril': 2, 'crispr': 1, 'desipramine': 2, 'proteasome inhibitors such as carfilzomib': 1, 'adenosine triphosphate production': 1, 'noninferiority': 1, 'periplocymarin': 3, 'pharmacokinetics': 1, 'nanoprobes': 1, 'antiplasmodial': 1, 'fluoride': 1, 'doxorubicin chemotherapy': 1, 'myricetin': 4, 'adenosine triphosphate depletion': 2, 'glutathione peroxidase ( gsh - px ) in intact cardiomyocytes': 1, 'agonists': 1, 'cardioactive therapies , possibly explaining the lack of association of risk categories with lvd occurrence .': 1, 'vincristine': 1, 'dexamethasone': 1, 'cytarabine': 1, 'hallucinogens': 1, 'diphenyltetrazolium bromide ( mtt )': 1, 'p21 cdc42': 3, 'glutathione': 1, 'methoxy polyethylene glycol ( methoxy polyethylene glycol )': 1, 'methoxy polyethylene glycol - s - pblg copolymer': 1, 'methoxy polyethylene glycol - s - pblg micelles': 1, 'epinephrine': 2, 'propranolol': 1, 'carvedilol': 1, 'metoprolol': 1, 'labetalol': 1, 'curcumin': 1, 'cmn': 1, 'aspartate amino transaminase ( aspartate transaminase )': 1, 'doxo': 4, 'icariin': 2, 'antibiotics': 1, 'analgesics': 1, 'anesthetics': 1, 'opioids': 1, 'ropivacaine': 2, 'analgesia': 1, 'unsaturated phospholipid': 1, 'beta - sodium glycerophosphate ( beta - gp )': 1, 'verapamil': 1, 'lamotrigine': 5, 'levetiracetam': 5, 'valproic acid ( lamotrigine only )': 1, 'levetiracetam serum / plasma levels with toxicity : a long - term retrospective review at an academic medical center " [ k. e. wood ,': 1, 'yohimbine': 6, 'hipsc': 2, 'yohimbine inhibited': 1, 'whereas yohimbine': 1}, 'toxicity': {'insulin': 1, 'hoxy)phenoxy)acetic acid ( lead compound': 1, 'intraperitoneally': 1, 'mercapturic acid': 1, 'quercetin': 6, 'pb+ quercetin group was fed with ration supplemented': 1, 'blood urea nitrogen ( blood urea nitrogen': 1, 'quercetin supplementation': 4, 'pb': 5, 'malondialdehyde': 13, 'glutathione peroxidase': 2, 'hdac': 1, 'histone deacetylase': 4, 'analgesic': 2, 'anesthetics': 1, 'isoflurane': 3, 'stereological': 1, 'methylimidazolium nitrate': 1, 'gossypium': 1, 'dreg': 2, 'antibiotic': 7, 'coelomocytes': 1, 'aromatic amino acids )': 1, 'sulfonamides ( sulfonamides )': 1, 'sulfonamides': 1, 'ecotoxicity': 1, 'antibiotics': 5, 'sulfadiazine': 1, 'sulfamethoxazole': 1, 'sulfamethazine': 1, 'arsenic trioxide ( arsenic trioxide )': 1, 'arsenic trioxide': 2, 'rapamycin': 1, 'antimalarials': 1, 'sixteen compounds': 1, 'carbamazepine': 1, 'ibuprofen': 3, 'triclosan': 1, 'antifungal': 1, 'zinc': 1, 'chlorobutanol': 5, 'cadmium': 2, 'imatinib': 8, 'erlotinib': 2, 'nilotinib': 1, 'dasatinib': 3, 'sorafenib': 2, 'amiodarone': 1, 'diclofenac': 3, 'transcriptomics': 1, 'ciguatoxin': 1, 'lactobacillus': 1, 'bifidobacterium': 1, 'fumonisin': 9, 'intragastrically': 1, 'platelets': 1, 'necroinflammation': 1, 'fumonisins': 1, 'metformin': 6, 'fluoroquinolone': 2, 'ciprofloxacin': 8, 'cometabolism': 1, 'mineral nanomedicine': 1, 'europium - doped calcium fluoride': 1, 'carbapenems': 1, 'chemotherapy': 31, 'trifluridine': 2, 'tipiracil': 2, 'ftd': 1, 'fluorouracil': 2, 'oxaliplatin': 10, 'amenability': 1, 'phosphatidylcholine': 1, 'cpx': 1, 'sphma7': 1, 'helichrysum': 1, 'arsenic': 5, 'peganum': 1, 'ellagic acid derivatives ( 3 ,': 1, 'gallic acid derivatives ( 5 ,': 1, 'phosphofructokinase': 1, 'admet': 1, 'mvocs': 2, 'ganoderma': 1, 'nitric oxide': 1, 'amino acid residues': 1, 'ericaria': 2, 'linoleamide': 1, 'palmitamide': 1, 'oleamide': 1, 'erucamide': 1, 'folin': 1, 'anticancer': 7, 'antifouling compounds': 1, 'red alga sphaerococcus coronopifolius': 2, 'bromosphaerol': 4, 'calcium salts': 1, 'levulinic acid': 2, 'calcium carbonate': 1, 'murashige': 1, 'analogs': 2, 'tansy': 1, 'mirtazapine': 7, 'potassium dichromate (': 1, 'selenium': 4, 'il-2': 1, 'cbd2': 1, 'celluclast': 1, 'faggion': 1, 'alectinib': 2, 'carboplatin': 1, 'cbdca': 3, 'cisplatin': 5, 'aprepitant': 1, 'docetaxel': 4, 'nanosponges': 1, 'dexamethasone': 4, 'antifouling': 1, 'antifouling sol - gel': 1, 'fe(iii': 2, 'glutathione ( gsh )': 1, 'superoxide dismutase ( superoxide dismutase )': 1, 'doxorubicin': 2, 'conatumumab': 1, 'irinotecan': 3, 'gemcitabine': 10, 'capecitabine': 5, 'pd.acute fish toxicity ( pd.acute fish toxicity )': 1, 'pure compounds': 1, 'microg': 3, 'octanol': 1, 'decanol': 1, 'bifenthrin': 1, 'caenorhabditis': 1, 'oscillospiraceae': 1, 'lachnoclostridium': 1, 'liposomal oxaliplatin': 1, 'mesalazine': 2, 'adlay': 1, 'brittanica': 1, 'gailardia': 1, 'antioxidant compounds': 1, 'free chlorine': 1, 'artemia': 1, 'lliver': 1, 'lactic acid': 1, 'methylprednisolone': 1, 'steroids': 1, 'immunosuppressants': 1, 'baclofen': 5, 'selenium ( selenium ) supplementation can restrict metal uptake by roots and translocation to shoots , which is one': 1, 'citrate': 2, 'amino acids': 1, 'subtoxic': 3, 'intracerebroventricular': 1, 'cysteine protease': 1, 'gefitinib': 8, 'pemetrexed': 1, 'hematological': 1, 'chemoradiation': 1, 'radiosensitizing': 1, 'microci': 2, 'vip152': 1, 'meclofenamate': 6, 'nonsteroidal': 1, 'copper chelating abilities': 1, 'steroid': 1, 'rifampicin': 1, 'isoniazid': 1, 'quinolone': 1, 'linezolid': 6, 'tb medicines': 1, 'honokiol': 1, 'curcumin nanoparticles ( curcumin - nanoparticles ) against copper oxide nanoparticle ( cuo - np)-mediated hepatorenal effects on behavioral performance , biochemical markers , antioxidants , inflammation , apoptosis , and histopathology in rats . study design : twenty wistar adult male rats were randomly divided into four groups ( n=5 )': 1, 'iotaiota': 1, 'gavaged': 1, 'curcumin - nanoparticles (': 1, 'curcumin - nanoparticles': 1, 'histopathological': 2, 'uric acid': 1, 'tamoxifen': 1, 'genistein': 1, 'apigenin': 1, 'nicotinic acetylcholine receptors': 3, 'rituximab': 1, 'cyclophosphamide': 1, 'vincristine': 1, 'prednisolone': 1, 'r - chop . methods : we developed a predictive model ( tolerability of r - chop in aggressive lymphoma [ trail ] ) on the basis of a training data set from the phase iii goya trial ( obinutuzumab with chop v r - chop in 1l diffuse large b-cell lymphoma ) using a composite binary end point , identifying patients who prematurely stopped or required reductions of r - chop . candidate predictive variables were selected on the basis of known baseline characteristics that contribute to patient frailty , comorbidity , and/or chemotherapy toxicity . trail was developed using an iterative trial - and - error modeling process to fit a logistic regression model . the final model was evaluated for robustness using a goya holdout data set and the phase iii main ( r - chop with or without bevacizumab': 1, 'spiro heterocycles were synthesized via': 1, 'isatoic anhydride': 1, 'barbituric acid / thiobarbituric acid': 1, 'etoposide': 1, 'oleic acid , tocopherol , methyl ester , diterpene alcohol , triterpene and fatty acid ester': 1, 'wasmann': 1, 'ethyl acetate': 1, 'photodynamic': 1, 'paclitaxel': 1, 'porphyrin prodrugs are synthesized': 1, 'chemo': 1, 'illudane glycosides ptesculentoside': 1, 'ptaquiloside': 2, 'nickel nanoparticles nanoparticles': 1, 'urothelial': 1, 'pembrolizumab': 1, 'enfortumab vedotin': 3, 'ghb': 8, 'exogenously': 1, 'pharmacokinetics': 2, 'gabaergic': 1, 'analogues': 1, 'herceptin': 4, 'tryptophan': 1, 'amino acid supplements': 2, 'probucol': 7, 'glutathione peroxidase ( glutathione peroxidase': 1, 'prx5': 1, 'manganese': 1, 'curcuma': 1, 'ethylene glycol': 1, 'propylene glycol': 1, 'tetradentate': 1, 'chelating ligands': 1, 'cobalt(ii': 1, 'nonnatural analogs': 1, 'panitumumab': 1, 'cannabidiol': 5, 'cox-2 inhibitor': 1, 'ecuphar': 1, 'microplastic': 1, 'chromium': 10, 'alanine amino transferase': 1, 'selenium ( selenium )': 1, 'selenate': 1, 'polygalacturonase': 1, 'superoxidase': 1, 'beta - galactosidase )': 1, 'hydrogen peroxide': 2, 'nanomaterial': 1, 'tempol conjugated beta - cyclodextrin and genistein': 1, 'sulfated steroids': 1, 'sulfatase': 2, 'polylactic acid': 1, 'plastics': 1, 'bioavailability': 1, 'methotrexate': 6, 'methacrylic acid': 1, 'methylene bis acrylamide ( methylene bis acrylamide )': 1, 'albino rabbits': 1, 'curcumin': 7, 'tyrosine kinase inhibitors ( tyrosine kinase inhibitors ) are molecular - targeted anticancer drugs': 1, 'tyrosine kinase inhibitors': 1, 'keratinocyte': 2, 'regorafenib': 1, 'pazopanib': 1, 'thrombogenicity': 1, 'binimetinib': 3, 'adjuvant': 1, 'bisphosphonate': 6, 'ibandronate': 1, 'zoledronic acid': 1, 'beta - lactam antibiotics ( amoxicillin and amoxicillin - clavulanate': 1, 'cefditoren': 1, 'macrolide': 1, 'fluoroquinolones': 1, 'polyphenolic compound': 1, 'curcumin exhibits immobilizing action on sperms , and at': 1, 'chemotherapeutic': 1, 'oocyte': 1, 'isovalent substitution': 1, 'cupric ions': 1, 'ado - trastuzumab emtansine ( t - dm1 )': 1, 'monoclonal antibody': 1, 'trastuzumab': 1, 'microtubule inhibitor emtansine': 1, 'valproic acid ( valproic acid )': 1, 'valproic acid analogues': 1, 'gadolinium': 1, 'ferulic acid': 2, 'ferulic acid exhibits various therapeutic actions by modulation of various signal transduction pathways such as nrf2': 1, 'ferulic acid include anti - apoptosis , antioxidant , anti - inflammatory , antidiabetic': 1, 'polyacrylic acid ( polyacrylic acid': 1, 'flavonoids': 1, 'chemopreventive': 1, '-9.0': 1, 'setac': 1}, 'ali': {'mvocs': 2, 'iodine complex': 2, 'ionic - iodine polymer complex with': 1, 'elemental iodine': 1, 'magnesium stearate ( magnesium stearate ) binary mixtures . micronized fluticasone propionate': 1, 'magnesium stearate': 1, 'magnesium stearate mixing': 2, 'pharmacokinetics': 1, 'shc4': 2, 'bleomycin': 2, 'jak': 2, 'normal saline': 2, 'intragastric': 2, 'chemotherapy': 7, '21.3mo': 1, 'bb': 1, 'xuanfei baidu': 7, 'glycyrrhizic acid': 1, 'dapagliflozin': 1, 'malondialdehyde': 8, 'nitric oxide': 5, 'dapagliflozin antioxidant': 1, 'selenoprotein': 1, 'anticoagulant medication . endovascular or open vascular revascularisation': 1, 'anticoagulation': 1, 'fangfeng': 1, 'il-5': 1, 'antiinflammatory': 1, 'asa': 4, 'myeloperoxidase': 2, 'amadori compounds': 1, 'sodium adducting cations': 1, 'antibiotic': 18, 'ciprofloxacin': 3, 'chloroquine': 4, 'rapamycin': 3, 'isovitexin': 7, 'pten': 1, 'vorapaxar': 1, 'aspirin': 1, 'analogues': 1, 'elastase inhibitor': 1, 'lenalidomide': 1, 'polymorphonuclear': 1, 'qingwenzhike': 3, 'interleukin-18': 1, 'isoorientin': 2, 'thalictrum': 3, 'il-2': 1, 'atg5': 1, 'sodium iodide': 2, 'radiopharmaceuticals': 1, 'resveratrol ( resveratrol )': 1, 'dexamethasone': 7, 'resveratrol': 6, 'lipopolysaccharide': 2, 'mrnas': 5, 'interactions': 2, 'jhep': 1, 'phosphoinositide': 3, 'eurycoma longifolia ( tongkat ali )': 1, 'isoscopoletin': 1, 'fluorofenidone': 1, 'melatonin receptor agonist with anti - inflammatory and antioxidant effects': 1, 'autophagy': 1, 'sirtuin': 6, 'thrombolytic': 1, 'embase': 2, 'cinahl': 1, 'beta inhibitor': 1, 'mtor': 1, 'hif1alpha': 1, 'telocytes': 1, 'beta inhibitors': 1, 'cochrane': 1, 'box-1': 1, 'prf1': 1, 'gzmb': 1, 'oasl': 1, 'hsp90aa1': 1, 'hydroxymethylfurfural': 1, 'fluticasone': 2, 'ufp': 2, 'nqo1': 1, 'propionate': 1, 'galactooligosaccharide': 1, 'flavonoid': 1, 'coumarin': 1, 'microg': 1, 'abts': 1, 'trolox': 1, 'terretonin': 4, 'agrimonia pilosa ethanol extract': 1, 'nitrous oxide': 3, 'napdh oxidase ( dpi )': 1, 'hydrochloric acid ( hydrochloric acid )': 2, 'hcl': 1, 'taurine': 1, 'nitrous': 5, 'dexmedetomidine': 2, 'chelerythrine': 1, 'tcmsp': 1, 'tcmio': 1, 'k inhibitor': 1, 'cytokine storm injection': 1, 'fluids': 4, 'antibiotics': 9, 'hyperoxia': 1, 'cytokine storm': 1, 'calycosin': 1, 'interferon genes inhibitor c-176 (': 1, 'interferon genes inhibitor': 2, 'interferon genes knockdown significantly decreased the phosphorylation of transcription factor': 1, 'interferon genes inhibitor can alleviate lipopolysaccharide - induced air-liquid': 1, 'acetaminophen': 1, 'insulin glargine': 2, 'detemir': 4, 'insulin': 3, 'glargine': 1, 'leptin': 1, 'streptozotocin': 2, 'broncho': 1, 'zdp': 1, 'bifendate': 1, 'physiologic saline ( normal , negative control )': 1, 'antioxidants superoxide dismutase': 1, 'vitamin d3': 2, 'calcitriol': 1, 'vitamin d3 supplementation prevents lipopolysaccharide - induced air-liquid': 1, 'antidepressants': 1, 'venlafaxine': 2, 'antipsychotic': 1, 'anakinra': 4, 'il-1 blockade': 1, 'nervilia': 5, 'il-6': 6, 'phytomedicine': 1, 'propionate receptor antagonist': 1, 'intratracheal': 3, 'hydrochloric acid': 3, 'propionate receptors': 1, 'hydrogen': 2, 'tbi': 3, 'pyroptosis': 2, 'salicylic acid': 3, 'microparticle': 1, 'adipic acid - it is anticipated that the poly - a particles represent a therapeutic strategy in acute respiratory distress syndrome with a rare opportunity': 1, 'metformin': 5, 'ambroxol': 2, 'methylprednisolone': 2, 'paraquat': 2, 'propofol': 6, 'oleic acid ( oleic acid )': 1, 'oleic acid group': 2, 'oleic acid': 2, 'oleic acid + ix group,': 1, 'albumin': 1, 'lldt-8': 4, 'dexmedetomidine antagonist yohimbine ( yohimbine )': 1, 'catecholamine': 1, 'yohimbine': 1, 'angiojet': 1, 'maresin': 3, 'plasminogen activator inhibitor ( pai)-1 ( smd :': 1, 'ang2': 1, 'interleukin': 1, 'il-8': 4, 'metrnbeta': 1, 'terbutaline': 3, 'transferase dutp nick - end labeling': 1, 'honokiol': 2, 'superoxide dismutase in bronchoalveolar lavage fluid ( bronchoalveolar lavage fluid': 1, 'superoxide dismutase': 2, '14(s)-hdha': 2, 'prostaglandin': 2, 'linolenic acid': 1, 'dmem': 1, 'peroxiredoxin': 2, 'abolishes': 1, 'dehydroepiandrosterone - sulfate': 1, 'omeprazole': 2, 'bergamottin': 2, 'tsrna-5002b': 1, 'tsrna-3045b': 1, 'tsrna-5005b': 1, 'naboandelus': 1, 'citrate': 1, 'extracellular citrate': 2, 'pro - interleukin-1beta': 1, 'adenosine - triphosphate ( adenosine-triphosphate )': 1, 'red mitochondrial superoxide': 1, 'semisynthetic': 1, 'plaur': 1, 'syringaresinol': 1, 'lidocaine': 9, 'nivolumab': 1, 'infliximab': 2, 'carbapenems': 2, 'ali': 1, 'tigecyclin': 1, 'colistin': 1, 'analgesic': 1, 'interleukin ( il)-1beta and prostaglandin e2 ( prostaglandin e2 )': 1, 'antioxidant compounds': 1, 'bronchoalveolar lavage fluid ( bronchoalveolar lavage fluid': 1, 'jak2': 1, 'luteolin': 1, 'quercetin': 1, 'coronavirus': 1, 'erythropoietin': 1, 'mitogen': 1, 'palrnatine': 1, 'dimethyl fumarate ( dimethyl fumarate': 1, 'dimethyl fumarate': 10, 'dimethyl fumarate ( dissolved in': 1, 'zinc metalloproteinase': 1, 'polyanionic sodium alginate ( naaig )': 1, 'intratracheally': 1, 'aldehyde': 5, 'matrix': 1, 'glycocalyx': 1, 'acetylcysteine': 10, 'canadian acetaminophen overdose': 1, 'paracetamol': 1, 'polyplexes': 1, 'hypochlorous acid ( hypochlorous acid': 1, 'hypochlorous acid concentration': 1, 'hypochlorous acid': 1, 'osteoprotegerin': 1, 'micrornas': 1, 'exosomes': 2, 'na(+),k(+)-atpase': 2}, 'metastasis': {'folfirinox': 1, 'immunoglobulin': 1, 'methylprednisolone': 1, 'photothermal': 4, 'chemokine ligand': 1, 'lr': 1, 'nonadjacent': 1, 'nomogram': 2, 'mineral nanomedicine': 1, 'europium - doped calcium fluoride': 1, 'chemotherapy': 98, 'trifluridine': 3, 'tipiracil': 3, 'ftd': 1, 'fluorouracil': 4, 'oxaliplatin': 8, 'cisplatin': 3, 'irinotecan': 3, 'clinicopathological': 2, 'heparin': 1, 'warfarin': 1, 'vitamin k antagonist': 1, 'anticoagulation': 2, 'isoniazid': 1, 'rifampin': 1, 'premetrexed': 1, 'carboplatin': 1, 'tfeb': 6, 'pn': 2, 'transendothelial': 1, 'mir-155_5p': 1, 'cytoscape': 1, 'cluego': 1, 'palisading': 1, 'histopathological': 1, 'paris saponin': 2, 'nitric oxide synthase': 1, 'suramin': 4, 'suramin compound derivatives synthesized herein show potential as novel therapeutic agents for their anti - proliferative activity via': 1, 'suramin compound': 1, 'ursolic acid ( ursolic acid': 1, 'anticancer': 2, 'ursolic acid': 6, 'tumourectomy': 1, 'hormonotherapy': 1, 'pseudoachalasia': 1, 'linoleic acid ( linoleic acid': 1, 'linoleic acid': 6, 'linoleic acid reduced gli2': 1, 'linoleic acid - mediated suppression of sox17 expression . these results suggest that linoleic acid promotes tumor cell stemness': 1, 'gli2 fragments via': 1, 'gli2': 2, 'doxorubicin': 1, 'anesthesia': 3, 'cnki': 1, 'wanfang': 1, 'anesthetics': 1, 'progesterone receptor (pr ( progesterone receptor )': 1, 'dimerization blocker , stattic ( s )': 1, 'nanocarrier': 1, 'stattic': 5, 'plga nanoparticles': 1, 'urothelial': 1, 'arginine methyltransferase': 1, "progesterone receptor (pr status . rates of high wilms' tumor 1-associated protein expression were 66.1": 1, 'abemaciclib': 3, 'letrozole': 1, 'steroid': 1, 'prednisolone': 2, 'progesterone receptor': 1, 'fulvestrant': 1, 'antibiotic': 1, 'nivolumab': 11, 'paclitaxel': 5, 's-1': 1, 'ramucirumab': 2, 'opioids': 1, 'steroids': 1, 'cause(s)and': 1, 'anastrozole': 2, 'leucovorin': 1, 'irinotecan(folfoxiri)plus': 1, 'panitumumab': 1, 'gemcitabine': 5, 'nab - paclitaxel': 3, 'pancreaticoduodenectomy': 1, 'chemoradiotherapy': 1, 'adjuvant chemotherapy': 4, 'folfiri': 5, 'progesterone': 3, 'docetaxel': 2, 'trastuzumab': 4, 'antibiotics': 1, 'bevacizumab': 5, 'capecitabine': 1, 'cetuximab': 2, 'rhv': 1, 'imatinib': 5, 'r - chop therapy achieved a complete response . a 21 - year - old female spotted seal ( phoca largha': 1, 'estrogen': 2, 'receptor alpha . tfeb - estrogen-related receptor alpha axis enhanced generation of pseudopodia': 1, 'phosphatidylcholine': 2, 'peptidyl arginine deiminase': 1, 'lidocaine': 8, 'sox': 1, 'folfox': 1, 'docetaxel(dtx)as': 1, 'chemotherapy(tc)and': 1, 'chemo': 2, 'fulvestrant)was': 1, 'immunochemotherapy': 1, 'gcs': 1, 'neo': 1, 'paln': 2, 'folfoxiri': 1, 'pegfilgrastim': 1, 'unresectable': 1, 'neoadjuvant chemotherapy': 2, 'epirubicin': 1, 'cyclophosphamide': 1, 'ssppd': 1, 'ilnm(4': 1, 'tamoxifen': 1, 'aromatase inhibitors': 1, 'cdk4/6 inhibitors': 1, 'nab - paclitaxel plus ramucirumab , then treated with nivolumab': 1}, 'polycystic ovary syndrome': {'insulin': 92, 'glucose': 11, 'peak insulin': 1, 'fasting insulin': 7, 'analgesics': 1, 'periodontopathogens': 1, 'letrozole': 45, 'adipocytokines': 1, 'curcumin': 12, 'polyphenolic compound': 1, 'curcumin exhibits immobilizing action on sperms , and at': 1, 'chemotherapeutic': 1, 'embase': 3, 'albuminuria': 1, 'hyperandrogenism': 10, 'flutamide': 1, 'spironolactone': 8, 'clomiphene': 16, 'kuntai': 4, 'estradiol': 15, 'berberis': 1, 'berberine': 2, 'dehydroepiandrosterone sulfate': 3, 'luteinizing hormone (lh / follicle - stimulating hormone (lh , testosterone': 2, 'antiandrogen': 2, 'adropin': 1, 'metatrim': 1, 'cholesterol': 2, 'fatty acid (tca oxidation': 1, 'testosterone': 4, 'dehydroepiandrosterone - sulfate ( dehydroepiandrosterone - s )': 1, 'polyunsaturated fatty acids ( polyunsaturated fatty acids )': 1, 'nct04738409.).estradiol': 1, 'steroid': 5, 'erbeta': 1, 'metformin': 60, 'normal saline water ( 0.9': 1, 'malondialdehyde': 4, 'il-6': 1, 'genistein': 4, 'gonadotropins': 2, 'diacerein': 2, 'serum insulin': 1, 'interleukin': 2, 'inflammasome': 1, 'valproate': 1, 'lamotrigine': 2, 'oxcarbazepine': 2, 'carbamazepine': 2, 'progesterone': 13, 'gpx3': 1, 'mrnas': 7, 'tamoxifen': 3, 'clomiphene citrate': 2, 'dehydroepiandrosterone': 7, 'androgens': 2, 'estrogens': 3, 'glucagon': 1, 'peripheral insulin resistance in the early phase of type 2 diabetes . in the skeletal muscle and liver , the atp surplus contributes to insulin resistance': 1, 'donor breastmilk': 1, 'ovarian insulin resistance in polycystic ovary syndrome remain elusive . methods : follicular fluid': 1, 'electroacupuncture': 7, 'indonesia': 1, 'folliculogenesis': 2, 'resveratrol': 5, 'resveratrol potently': 1, 'estrogen': 2, 'oxytocin': 5, 'arginine - vasopressin , avp )': 1, 'phoenixin': 1, 'pnx': 1, 'lipidomic': 1, 'vitamin - like nutrients ( bioflavonoids and alpha - lipoic acid (tca )': 1, 'selenium': 1, 'chromium': 1, 'omega-3 fatty acids': 1, 'probiotics': 4, 'placentaspecific': 2, 'fasting insulin ( fins : wmd -3.40': 1, 'serum metformin concentrations': 1, 'kisspeptin': 1, 'receptor antagonist': 1, 'b analogs': 1, 'vitamin b12': 1, 'vitamin d': 3, 'prebiotics': 2, 'cochrane databases': 1, 'synbiotics': 2, 'pioglitazone': 6, 'ferriman - gallwey score ( f - g )': 1, 'fasting insulin ( fasting insulin': 1, 'genecards': 1, '13,823': 1, 'melatonin': 1, 'glucose transporter ( glut4 )': 1, 'palmitic acid (tca ( physical activity )': 1, 'esr2': 2, 'latvia': 1, 'bile acid (tca and 24 bile acid (tca metabolites': 1, 'taurocholic acid (tca ( taurocholic acid )': 1, 'glycochenodeoxycholic acid (tca ( glycochenodeoxycholic acid )': 1, 'resveratrol possesses anti - inflammatory , antioxidant and antidiabetic properties . the purpose of this study was to evaluate the potential effectiveness of resveratrol in polycystic ovary syndrome based': 1, 'ovariectomy': 1, 'ovulate': 1, 'dysglycemia': 1, 'fasting insulin resistance ( homeostatic model assessment of insulin': 1, 'psychiatric medication': 1, 'statins': 5, 'statin': 1, 'do insulin sensitizing agents such as': 1, 'myoinositol': 3, 'ferriman': 1, 'ferriman gallwey': 2, 'bushen': 3, 'cyproterone': 1, 'norepinephrine': 1, 'hydroxyindoleacetic acid (tca (': 1, 'luteinizing hormone': 1, 'bushen jieyu tiaochong formula': 1, 'atf4': 1, 'drospirenone': 1, 'scopus': 1, 'cochrane': 1, 'orlistat': 8, 'acarbose': 2, 'rosiglitazone': 2, 'sitagliptin': 1, 'lipotoxicity': 1, 'glycerophosphocholines': 1, 'sphingolipids': 1, 'rhamnosus gg': 1, 'free testosterone': 1, 'luteinizing hormone , luteinizing hormone': 1, '17,076': 1, 'antioxidative vitamins ( vitamins )': 1, 'cochrane library databases': 1, 'cinahl': 2, 'pipelle': 1, 'hormone agonist protocol': 2, 'hormone agonist': 1, 'hormone agonist cycles': 1, 'mdm2': 1, 'hyperinsulinism': 1, 'cytoscape': 2, 'ereg': 1, 'wenshentiaojing': 1, 'luteinizing hormone (lh and follicle - stimulating hormone (lh , serum total cholesterol': 1, 'gpr120 agonist decreased insulin resistance in the polycystic ovary syndrome rat model but improved the ovarian function . it is suggested that gpr120 plays a vital role in suppressing insulin resistance , regulating ovary function and decreasing lipid accumulation in the liver , demonstrating that targeting gpr120 could be an effective method for the improvement of pcos.polycystic ovary syndrome (ms ( polycystic ovary syndrome )': 1, 'merck': 2, 'cyclopamine': 1, 'allopregnanolone': 1, 'serum leptin /': 1, 'bacteroidetes': 1, 'blautia': 3, 'butyric acid (tca , reduced after sleeve gastrectomy . sleeve gastrectomy significantly ameliorated polycystic ovary syndrome - related symptoms such as hyperandrogenism': 1, 'pentraxin': 2, 'lipid': 1, 'drosha': 1, 'anticoagulation': 1, 'apixaban': 2, 'vitamin d3 supplementation : either a microencapsulated liposomal': 1, 'immunoreactive insulin': 2, 'vitamin d supplementation': 1, 'vitamin d3': 2, 'dihydrotestosterone': 2, 'progesterone receptor (er , homeobox a11 mrna expression and placental estrogen - related receptor (er beta and trophoblast - specific protein alpha mrna expression . collectively , our data provide insight into how n-acetylcysteine': 1, 'gonadotropin': 1, 'rbpms': 1, 'leptin': 4, 'intracerebroventricular': 2, 'extracellular glutathione peroxidase': 1, 'glutathione peroxidase': 2, 'antibiotic': 1, 'dorea': 1, 'dehydroepiandrosterone sulphate ( dehydroepiandrosterone sulphate )': 1, 'alpha - lipoic acid (tca on clinical , endocrine and metabolic features of women affected by polycystic ovary syndrome . methods : in this pilot cohort study , 60 women ( 30 hyperinsulinemic and 30 normoinsulinemic patients ; age 15 - 34 years ) were enrolled and clinical , hormonal and metabolic parameters were evaluated before and after a six - months treatment with alpha - lipoic acid (tca': 1, 'progestin': 1, 'synthetic oxytocin': 1, 'superoxide dismutase ( superoxide dismutase )': 1, 'gsh': 1}, 'tumour': {'cytotoxic': 1, 'chemotherapy': 37, 'immunostaining': 1, 'tamoxifen': 16, 'hydroethanolic': 2, 'nitric oxide': 2, 'malondialdehyde': 1, 'glutathione peroxidase ( gsh - px )': 1, 'trichogerminomas': 1, 'alizarin red stainings': 1, 'osteopontin': 1, 'antibiotics': 1, 'clindamycin': 1, 'rifampicin': 6, 'immunohistochemistry': 1, 'chemo': 2, 'octreotide': 2, 'telotristat': 1, 'amplatzer': 1, 'tumourectomy': 1, 'hormonotherapy': 1, 'urothelial': 1, 'arginine methyltransferase': 1, 'fluorouracil': 1, 'peptidyl arginine deiminase': 1, 'imatinib': 3, 'cisplatin': 17, 'agglutinin': 1, 'haematological': 2, 'inflammatories': 1, 'cochrane databases': 1, 'vincristine': 2, 'actinomycin': 2, 'doxorubicin': 9, 'epirubicin': 1, 'ifosfamide': 1, 'carboplatin': 7, 'etoposide': 19, 'cyclophosphamide': 3, 'ccr6': 1, 'embase': 1, 'medline': 1, 'akaike': 1, 'pn': 1, 'tranexamic acid ( tranexamic acid )': 1, 'tranexamic acid': 1, 'tranexamic acid in haematuria': 1, 'polylactic acid filament': 1, 'sugemalimab': 6, 'paclitaxel': 8, 'pemetrexed': 1, 'bleomycin': 3, 'etoposide phosphate': 2, 'hydrocortisone': 1, 'promethazine': 1, 'adrenaline': 1, 'fluids': 1, 'oxygen': 1, 'spironolactone': 6, 'steroid': 4, 'checkpoint inhibitor': 1, 'taxane': 1, 'centre': 1, 'ttk': 2, 'cdc20': 2, 'abiraterone': 1, 'steroids': 1, 'g1': 1, 'characterising': 1, 'multistructure': 1, 'bromelain': 2, 'acetylcysteine': 3, 'gemcitabine': 3, 'chemoimmunotherapy': 1, 'pembrolizumab': 1, 'blockade': 1, 'ctcae': 1, 'nitric oxide ( nitric oxide': 1, 'e)-9': 2, 'raloxifene': 4, 'nephrotoxicity': 1, 'vitamin d': 1, 'vitamin d synthesis': 1, 'vitamin d receptor ( vitamin d receptor )': 1, 'butyrate': 1, 'acetate': 1, 'chemoradiotherapy': 2, 'fondazione': 1, 'gemelli': 1, 'betegeknel': 1, 'gyakran nem lehetseges vagy nehezitette valik': 1, 'gasztroszkop': 1, 'szajon': 1, 'torteno': 1, 'rosszindulatu': 1, 'orv hetil': 2, 'trismus': 1, 'nab - paclitaxel': 1, 'fisetin': 2, 'phf10': 5, 'pyradiomics': 1, 'wilcoxon': 2, 'tumourigenesis': 1, 'nivolumab': 4, 'cabozantinib': 5, 'suvpeak': 3, 'suvapex': 1, 'sorafenib': 3, 'antifibrotic': 1, 'proangiogenic': 1, 'telomerase inhibitors , anti - angiogenesis agents': 1, 'bazedoxifene': 6, 'panitumumab': 1, 'amino acid': 1, 'ipilimumab': 2, 'perfluorohexane': 7, 'infliximab': 4, 'hypokalaemia': 1, 'galectin-3 inhibitor': 2, 'tocilizumab': 1, 'rituximab': 5, 'methotrexate': 1, 'braf': 1, 'trametinib dimethyl sulfoxide (': 1, 'atezolizumab': 1, 'bevacizumab': 1, 'vinblastine': 4}, 'ovarian cancer': {'chemotherapy': 110, 'paclitaxel': 30, 'msh6': 1, 'msh2': 1, 'niraparib': 2, 'haematological': 1, 'carboplatin': 23, 'adjuvant chemotherapy': 1, 'bevacizumab': 17, 'cisplatin': 61, 'neoadjuvant chemotherapy': 5, 'chemo': 9, 'tlr3 ligands': 1, 'rintatolimod': 1, 'celecoxib': 1, 'interferon-a was': 1, 'mest(high)brca1(high': 1, 'itpkb': 2, 'poly adenosine diphosphate ribose polymerase )': 1, 'anticancer': 4, 'veliparib': 2, 'nek4': 1, 'alpha': 1, 'opioid agonist d': 1, 'methadone': 8, 'analgesic': 2, 'kinase inhibitor': 1, 'bazedoxifene': 5, 'nicotinamide adenine dinucleotide ( nadh )': 1, 'tamoxifen': 2, 'crispr': 1, 'fatty acid oxidation': 1, '12,337': 1, 'cancer': 8, 'poly adenosine diphosphate ribose polymerase ) inhibitors': 1, 'poly adenosine diphosphate ribose polymerase inhibitors have been used in clinical practice . however , patients with platinum - resistant relapsed ovarian cancer cases still have a poor prognosis and there is an unmet need': 1, 'wilcoxon': 1, 'fe(iii': 2, 'anesthesia': 1, 'exosomes': 1, 'rapamycin inhibitors': 1, 'nomogram': 4, 'gepia': 1, 'ropivacaine': 2, 'dexmedetomidine': 1, 'normal saline': 2, 'analgesia': 7, 'sufentanil': 1, 'ondansetron': 1, 'flurbiprofen': 1, 'plga': 5, 'medline': 1, 'scopus': 1, 'hexon': 1, 'cddp': 1, 'ap-1': 1, 'camrelizumab': 1, 'famitinib': 1, 'hcg11': 1, 'daidzein': 5, 'genistein': 2, 'tertiles': 1, 'breastfeeding': 1, 'phy34': 4, 'poly adenosine diphosphate ribose polymerase cleavage and annexin v staining . compounds with a diphyllin structure similar to phy34 have been shown to inhibit the atp6v0a2 subunit of v(vacuolar)-atpase . therefore , atp6v0a2 wild - type and atp6v0a2 v823 mutant cell lines were tested with phy34': 1, 'mir-133a': 1, 'mir-133a inhibitor': 1, 'sapporo': 1, 'l - methionine': 1, 'mir-551b-5p': 1, 'vitamin d3': 1, 'calcitriol': 4, 'calcemic': 1, 'vitamin d analogs ( an1,25ds )': 1, 'vitamin d receptor ( vitamin d receptor )': 1, 'ang-(3': 1, 'folate receptor ( folate receptor ) alpha and': 1, 'amino acids': 1, 'folate transporter': 1, 'hyperthermic': 7, 'atf4': 1, 'chop': 1, 'bax': 1, 'proteasome inhibitor': 1, 'bortezomib': 1, 'poly adenosine diphosphate ribose polymerase ) inhibitors ( poly (adp-ribose) polymerase inhibitors )': 1, 'tricarboxylate': 1, 'molybdenum disulfide ( mos2 )': 1, 'bovine serum albumin': 1, 'electroconductivity': 1, 'adenosine': 1, 'intercellular interactions': 1, 'beta inhibitor': 2, 'youden': 1, 'fluorouracil': 1, 'carcinoembryonic': 1, 'mrnas': 2, 'nivolumab': 3, 'steroid': 3, 'normothermic': 1, 'epinephrine': 5, 'platinum chemotherapy': 1, 'skov-3': 1, 'antitumor': 1, 'autophagy': 1, 'histone deacetylase': 7, 'nagasaki': 1, 'ginkgolic acid': 5, 'dsmo': 1, 'transwell': 1, 'microrna-30': 3, 'gemcitabine': 3, 'hcg18': 3, 'shrna': 1, 'lysophosphatidic acid': 6, 'lysophosphatidic acid ( lysophosphatidic acid': 1, 'lysophosphatidic acid receptors (cars ( lpa receptors )': 1, 'lysophosphatidic acid receptor': 1}, 'infertility': {'syngeneic': 1, 'taurine transporter ( taut /': 1, 'guanidinoacetic acid (gaa ( guanidinoacetic acid )': 1, 'probenecid': 1, 'estradiol': 9, 'progesterone': 8, 'progestin': 9, 'levonorgestrel': 1, 'etomidate': 4, 'analgesic': 1, 'propofol': 3, 'intraperitoneally': 1, 'detortion': 1, 'ovulation': 1, 'letrozole': 22, 'clomiphene citrate': 6, 'clomiphene': 13, 'livebirth': 5, 'takeda': 1, 'roche': 1, 'hormone agonist': 2, 'cancer': 1, 'cinahl': 1, 'amino acid (gaa sequence in testis-specific protein y-encoded 1 protein': 1, 'noninterventional': 1, 'merck': 18, 'darmstadt': 6, 'germany': 2, 'theramex': 1, 'ferring pharmaceuticals a / s , grant': 1, 'chemotherapy': 5, 'oocyte': 1, 'adalimumab': 1, 'malondialdehyde': 6, 'inactivators': 1, 'zika': 1, 'intracytoplasmic sperm injection ( intracytoplasmic sperm injection': 1, 'intracytoplasmic sperm injection': 5, 'vitamin e': 3, 'vitamin e (': 2, 'oestradiol': 1, 'endometritis': 1, 'antibiotics': 1, 'hormones': 1, 'isotretinoin': 1, 'benzodiazepines': 1, 'statins': 1, 'tetracyclines': 1, 'irisin': 1, 'thyroid replacement therapy . the association between body mass index and subclinical hypothyroidism': 1, 'sperm': 1, 'insulin': 8, 'multivitamins': 1, 'folic acid (gaa supplements': 1, 'kindara.com': 1, 'berberis': 1, 'berberine': 2, 'contraceptives': 1, 'blaschko': 1, 'circulating insulin': 1, 'metformin': 4, 'intracytoplasmic sperm': 1, 'antisperm': 12, 'gonadotropins': 2, 'aase': 1, 'ejner': 1, 'mir-193a-5p': 1, 'artificial insemination': 2, 'hsalt': 1, 'normoxia': 1, 'o2': 1, 'spermatocytes': 1, 'spermatids': 2, 'globozoospermia': 1, 'bromocriptine': 5, 'dopamine': 2, 'jinfeng': 3, 'ceftriaxone': 2, 'doxycycline': 2, 'penicillin': 2, 'moxifloxacin': 2, 'nitroimidazoles': 1, 'metronidazole': 1, 'chromatin': 1, 'fatty acid (gaa oxidation': 1, 'crispr': 1, 'cct6b': 1, 'glucose': 2, 'scopus': 2, 'embase': 2, 'bibliographies': 1, 'hydroxybutyryllysine': 1, 'lysinecrotonyllysine': 1, 'methyllysine': 1, 'kac': 1, 'lysineacetyllysine': 1, 'kpr': 1, 'normal saline water ( 0.9': 1, 'il-6': 1, 'synthetic oestrogen diethylstilbestrol ( diethylstilbestrol )': 1, 'diethylstilbestrol': 7, 'cry1': 4, 'per2': 1, 'bmal1': 1, 'ferring': 2, 'pharmasure': 1, 'bessins': 1, 'dermatomyositis': 1, 'methotrexate': 1, 'salazopyrine': 1, 'cyclophosphamide': 1, 'vitamin c ( vitamin c )': 1, 'antioxidant supplements': 1, 'vitamin c ( 600 microm )': 2, 'hyperoside': 3, 'vitamin c': 3, 'shanghai municipal science': 1, 'shanghai': 5, 'shuguang': 1, 'phosphoglycerate': 1, 'busulfan': 3, 'loboob': 3, 'genistein': 4, 'steroid': 3, 'choline': 3, 'omega-3': 2, 'omega-3 ( 10.78 + /- 1.71 )': 1, 'transmembrane protease serine': 1, 'transcriptional': 1, 'ashwagandha': 1, 'estrogen': 1, 'tamoxifen': 3, 'faslg': 3, 'coincubation': 3, 'mrnas': 1, 'hyperlipidemic': 1, 'intratesticular': 1, 'hysterosalpingography': 1, 'gonadotropin': 1, 'subfertile': 1, 'clomiphene citrate ( clomiphene citrate': 1, 'bagcilar': 1, 'istanbul': 1, 'maxqda': 1, 'vandhyatva': 1, 'medline': 1, 'crem': 6, 'protamine': 1, 'activator': 1, 'lr': 1}, 'pancreatic cancer': {'chemotherapy': 53, 'inhalational anesthetics': 1, 'anesthesia': 10, 'inhalational': 1, 'inhalational anesthetics at kyushu university hospital between december': 1, 'gemcitabine': 55, 'capecitabine': 6, 'stk11': 1, 'nab - paclitaxel': 7, 'nab - paclitaxel combination': 1, 'nab-paclitaxel': 5, 'chemoradiation': 2, 's-1': 1, 'neoadjuvant chemotherapy': 6, 'vip152': 1, 'circrna': 1, 'anticoagulation': 1, 'fluorouracil': 3, 'epirubicin': 1, 'cyclophosphamide': 1, 'anticancer': 3, 'resveratrol ( resveratrol ) inhibits cancer (aspc-1 cell proliferation , migration , and invasion and promotes apoptosis . elevated expression of ryanodine receptor type 2 ( ryanodine receptor type 2 )': 1, 'resveratrol anticancer effects with ryanodine receptor type': 1, 'resveratrol': 2, 'resveratrol inhibits proliferation , migration , and invasion and suppresses ryanodine': 1, 'carboplatin': 1, 'doxorubicin': 3, '2clibmeca': 1, 'a3arspecific': 1, 'nab - paclitaxel ( gemcitabine plus nab-paclitaxel )': 1, 'folfirinox': 5, 'nab-paclitaxel chemotherapy combinations': 1, 'nab-paclitaxel regimens as a first - line treatment of metastatic pancreas cancer . in clinical routine , it is still unclear which regiment is more effective . the present study showed increased survival (os parameters with folfirinox': 1, 'paclitaxel': 2, 'nek4': 1, '22-': 1, 'ubl3': 1, 'bromelain': 2, 'acetylcysteine': 3, 'erlotinib': 3, 'chemoradiotherapy': 3, 'tregulatory': 1, 'fisetin': 2, 'phf10': 5, 'resectable': 2, 'monotherapy': 1, 'gliomaassociated': 3, 'fluorescein isothiocyanate ( cs /': 1, 'nomogram': 4, 'perfluorooctanoic acid ( perfluorooctanoic acid': 1, 'perfluorooctanoic acid': 2, 'nitric oxide synthase': 1, 'amanita': 1, 'silymarin compounds': 1, 'kras': 1, 'heterotypic': 1, 'soluble alcam': 1, 'abr': 1, 'hdac inhibitors ( hdac inhibitors ) in pancreatic ductal adenocarcinoma . this review summarizes the mechanisms associated with success and failure of hdac inhibitors in pancreatic ductal adenocarcinoma and discusses': 1, 'antecolic': 2, 'embase': 1, 'pancreaticoduodenectomy': 2, 'ag': 1, 'albumin': 1, 'adenosine triphosphate binding pocket . therefore , we assessed its ability to induce apoptosis ( which increased 1.5-': 1, 'bik': 1, 'desmoplastic': 1, 'unresectable': 2, 'mitomycin c': 1, 'epirubicin hydrochloride': 1, 'farnesyl transferase inhibitor': 1, 'photothermal': 3, 'boronic acid ( boronic acid )': 1, 'boronic acid - ligand fluorescence conjugate can effectively target multiple cancer stem cells': 1, 'chemo': 1, 'hydrogel precursor solution': 1, 'analgesia': 9, 'adp': 1, 'adenosine triphosphate': 2, 'posttreatment': 1, 'erastin': 1, 'rsl3': 1, 'hpa': 1, 'pd-1': 1, 'proton boron fusion therapy ( proton boron fusion therapy )': 1, 'proton boron fusion therapy in pancreatic cancer (aspc-1 . the ( 19)f - bpa carrier': 1, 'fatty acid binding protein 4 or the - single - point mutant fatty acid binding protein 4 ( r126q , fatty acid binding site mutant )': 1, 'clinicopathological': 1, 'adjuvant': 1, 'pancreatogastrostomy': 1, 'dindo': 1, 'nab': 1, 'medtronics': 1, 'opioid': 5, 'opioids': 2, 'omps': 3, 'doxorubicin hydrochloride': 1, 'chitinase': 5, 'chemosensitivity': 1, 'multiagent chemotherapy ( multiagent chemotherapy )': 1, 'multiagent chemotherapy': 2, 'durvalumab': 1, 'adenosine triphosphate ( adenosine triphosphate ) production in a galactose - containing medium resulting in significant cytotoxicity . importantly , 64 ( dx3 - 234 )': 1, 'dihydrofuran': 1, 'doublecortinlike': 2, 'cdk inhibitors': 1, 'mir1291': 2, 'nab - paclitaxel (': 1, 'nab-paclitaxel )': 1, 'anabolic': 1, 'prodrugs': 1, 'osteopontin': 5, 'shrna': 1, 'fatty acid': 1, 'asparaginase': 16}, 'her2-positive breast cancer': {'trastuzumab': 295, 'pertuzumab': 29, 'chemotherapy': 61, 'neoadjuvant chemotherapy': 7, 'fluorouracil': 7, 'epirubicin': 8, 'cyclophosphamide': 11, 'docetaxel': 16, 'neosphere': 2, 'tryphaena': 1, 'herceptin': 40, 'citrate ions': 1, 'clinicopathological': 1, 'estrogen receptor (pgr ( estrogen receptor )': 1, 'progesterone receptor (pgr ( progesterone receptor ) status , in which er-/pgr + tended to present the worst prognosis . conclusion : this study revealed profound heterogeneity associated with hormone receptor status in the clinical outcomes of human epidermal growth factor receptor 2 - positive breast cancer regarding clinicopathological': 1, 'capecitabine': 17, 'deruxtecan': 7, 'zenocutuzumab': 1, 'emtansine': 13, 'carboplatin': 6, 'primaquine': 2, 'ttre': 1, 'neoadjuvant chemotherapy ( neoadjuvant chemotherapy': 2, 'fty720': 1, 'taxane': 8, 'tucatinib': 2, 'arachidonic acid': 2, 'anthracycline': 13, 'neoadjuvant anti - human epidermal growth factor receptor': 1, 'her2dx': 1, 'paclitaxel': 17, 'neoadjuvant': 9, '1bb monoclonal antibody': 6, 'tubo': 1, '1bb monoclonal antibody combination therapy had a synergistic antitumor effect at the initial treatment': 1, '1bb monoclonal antibody combination therapy': 1, 'fulvestrant': 5, 'pyrotinib': 10, 'rapamycin': 10, 'lapatinib': 53, 'horseradish peroxidase ( horseradish peroxidase )': 1, 'anastrozole': 3, 'hsa': 1, 'hormone receptor': 1, 'margetuximab': 2, 'irrs': 1, 'ado - trastuzumab emtansine ( t - dm1 )': 1, 'kinase inhibitors': 1, 'nanobodies': 1, 'amino acid': 1, 'cdr1': 1, 'doxorubicin': 2, 'msns': 1, 'tzmsc': 1, 'dota': 1, 'her2])-based': 1, 'mmp2': 1, 'uridylyl phosphate adenosine': 1, 'lysine': 1, 'vojvodina': 1, 'bengbu': 1, 'affibody molecule ( 6 - 7 kda )': 1, 'affibody': 3, 'estrogen receptor )': 4, 'pembrolizumab': 1, 'atezolizumab': 2, 'durvalumab': 1, 'nivolumab': 1, 'antidiarrheal': 1, 'loperamide': 2, 'colestipol': 1, 'antidiarrheal medications in a real - world clinical setting': 1, 'ace inhibitors': 1, 'beta - blockers': 1, 'statins': 1, 'anticancer': 2, 'diphenyltetrazolium bromide': 1, 'everolimus': 2, 'dasatinib': 2, 'ace - i': 1, 'progesterone': 2, 'estrogen receptor / progesterone positivity rate (dcr was 72': 1, 'nab - paclitaxel was preferred': 1, 'cetuximab': 2, 'peg - filgrastim was prophylactically administered': 1, 'oligometastatic': 1, 'ado - trastuzumab ( t - dm1 )': 1, 'oleanolic acid ( oleanolic acid )': 1, 'oleanolic acid': 2, 'pharmacodynamics': 1, 'pharmacokinetics': 1, 'cytotoxic': 1, 'pd-1': 1, 'rxr agonist': 1, 'concomitantly': 1, 'pertu': 1, 'pharmacokinetic': 1, 'letrozole': 4, 'aromatase inhibitor ( aromatase inhibitor': 1, 'nomogram': 1, 'alpha ( estrogen receptor )': 1, 'progesterone receptor (pgr ( progesterone )': 3, 'estrogen receptor - progesterone - human epidermal growth factor receptor': 1, 'cdk4/6 inhibitors': 1, 'bioequivalence': 1, 'humanized mucin': 1, 'dodecyl sulfate - polyacrylamide gel': 1, 'neoadjuvant pertuzumab': 1, 'her-2 blockade and taxanes': 1, 'thermotoga': 1, 'thalidomide': 5, 'cereblon': 1, 'recombinant humanized anti - human epidermal growth factor receptor 2 monoclonal antibody (nab': 1, 'tz': 1, 'beclin': 1, 'selenite': 1, 'ttfields': 1, 'docked ligands': 1, 'ofdocetaxel': 1, 'eugenol': 1, 'threonine kinase': 1, 'progesterone receptor (pgr status [ hormone receptor , 3.12 ; 95 % confidence interval ( confidence intervals )': 1, 'til': 1, 'tyrosine kinase inhibitor ( tyrosine kinase inhibitor ) with promising efficacy in the human epidermal growth factor receptor-2 ( human epidermal growth factor receptor 2 ) positive breast cancer . the phase iii phoebe study proved that pyrotinib plus capecitabine': 1, 'vinorelbine': 1, 'biosimilars': 1, '95%ci': 1, 'estrogen': 1, 'progesterone receptor (pgr negativity and human epidermal growth factor receptor-2 positivity . after neoadjuvant therapy , the tumor in her left breast reduced in size , but the lymph nodes remained swollen . mastectomy and axillary lymph node dissections were performed . in the pathological findings , epithelioid cell granuloma was observed in the lymph nodes . based on these findings , lymph node swelling was attributed to a sarcoid - like reaction . clinical discussion : slrs have been reported in 4 - 14': 1, 'rapamycin inhibitors': 1, 'cisplatin': 4, 'alamar blue': 1, 'annexin': 1, 'her3': 1, 'ado - trastuzumab': 1, 'ribociclib': 5, 'ado': 1, 'irccs': 1, 'gemelli': 1, 'polyclinic': 1, 'dendrimers functionalized with anti - human epidermal growth factor receptor 2 vhhs': 1, 'adjuvant chemotherapy': 1, 'neoadjuvant chemotherapy with ph - fech': 1, 'noncardiac': 1, 'nab - paclitaxel plus': 1, 'estrogen receptor ( p =': 1, 'progesterone receptor ( p = 1.0 )': 1, 'adjuvant': 1, 'pim1': 1, 'pim1 inhibitor': 3, 'cardiotoxicity': 2, "humanized monoclonal antibody (nab against cd47 , blocks cd47 's": 1, 'rituximab': 3, 'estrogen receptor / progesterone levels': 1, 'estrogen receptor / progesterone level might be associated with better dfs.intercellular mechanisms by which the stromal microenvironment contributes to solid tumor progression and targeted therapy resistance remain poorly understood , presenting significant clinical hurdles': 1, 'bioinformatic': 1}, 'inflammation': {'analgesia': 13, 'bupivacaine': 3, 'fentanyl': 2, 'saline': 1, 'intragastrically': 1, 'malondialdehyde': 9, 'glucocorticoids': 1, 'tribulus terrestris saponins ( terrestris saponins )': 1, 'terrestris saponins (': 1, 'insulin': 9, 'terrestris saponins , at': 1, 'terrestris saponins helped in alleviation of insulin': 1, 'terrestris saponins as a promising candidate that may alleviate the inflammatory burden , insulin resistance and adipokine': 1, 'gliosis': 1, 'chemometrics': 1, 'adipokines': 1, 'resistin': 1, 'esculetin': 1, 'albuminuria': 1, 'pyrrolizidine': 1, 'folic acid': 13, 'folic acid peroxisomal beta - oxidation': 1, 'mildronate': 1, 'lachnoanaerobaculum': 1, 'hallii': 1, 'bifidobacterium': 4, 'rikinella': 1, 'christensenellaceae': 1, 'nonmodel': 2, 'beta-blockers )': 1, 'beta-blockers in patients with ascites and discuss the complex interplay among their hepatic , systemic , and renal hemodynamic effects in this scenario . the aim of this study was to further elucidate the molecular mechanisms that mediate pathologic foreign body response ( foreign body response )': 1, 'steroid': 4, 'duration': 1, 'lactobacillus': 2, 'eotaxin': 1, 'rupatadine': 3, 'peroxynitrite': 1, 'chemotherapy': 1, 'annexin': 1, 'statin': 1, 'leucine': 1, 'isoleucine biosynthesis , glutathione metabolism': 1, 'beta - hydroxybutyrate ( beta-hydroxybutyrate )': 1, 'fatty acid': 4, 'beta-hydroxybutyrate': 1, 'quantitative insulin sensitivity check index rquicki - beta-hydroxybutyrate': 1, 'nitric oxide': 3, 'divalent cations ( magnesium , zinc': 1, 'tamoxifen': 16, 'hydroethanolic': 2, 'glutathione peroxidase ( gsh - px )': 1, 'sargachromenol': 1, 'potassium dichromate (': 1, 'selenium': 4, 'il-2': 3, 'veraflo': 1, 'akaike': 1, 'antifungal': 2, 'lavage': 3, 'protease inhibitor': 1, 'bfgf': 1, 'chondral': 1, 'fibrinolysis': 1, 'ctgf': 1, 'caenorhabditis': 1, 'oscillospiraceae': 1, 'lachnoclostridium': 1, 'il-5': 1, 'il-9': 1, 'streptozotocin': 2, 'fasting insulin': 2, 'estradiol': 5, 'leptin': 3, 'antibiotics': 3, 'clindamycin': 1, 'rifampicin': 6, 'immunohistochemistry': 1, 'bleomycin': 1, 'analgesic': 9, 'opiates': 1, 'tetrodotoxin': 1, 'corticosteroid': 2, 'corticosteroids': 1, 'rapamycin': 2, 'subgingival': 2, 'desulfobulbaceae': 1, 'mycoplasmataceae': 1, 'campylobacteraceae': 1, 'muribaculaceae': 1, 'streptococcaceae': 1, 'gemellaceae': 1, 'megasphaera': 1, 'romboutsia': 1, 'rothia': 1, 'supragingival': 1, 'chemo': 1, 'pembrolizumab': 2, 'opioid analgesic dipeptide': 1, 'morphine': 1, 'infliximab': 7, 'royal jelly': 1, 'folic acid ( folic acid': 1, 'folic acid (': 1, 'superoxide dismutase': 1, 'tpsa': 3, 'bevacizumab': 4, 'ranibizumab': 3, 'triamcinolone': 1, 'folic acid revealed': 1, 'methylprednisolone': 2, 'cyclophosphamide': 1, 'asd).linoleic acid': 3, 'asd).linoleic acid reduced gli2': 1, 'asd).linoleic acid -': 1, 'gli2 fragments via': 1, 'gli2': 2, 'ovalbumin': 2, 'aberrance': 1, 'pleiotrophin': 1, 'jak1': 1, 'faecalibaculum': 1, 'dubosiella': 1, 'zymosan': 1, 'dangshen erling decoction ( dangshen erling decoction': 1, 'dangshen erling': 2, 'dangshen erling decoction': 4, 'sebia': 1, 'prevotella': 1, 'porphyromonas': 1, 'folic acid ( 22:4 )': 1, 'pyruvic acid': 1, 'amino acids': 1, 'succinate': 1, 'itaconic acid': 1, 'amino acid': 1, 'itaconic acid positively correlated with streptococcus . conclusion : in the lower respiratory tract microenvironment , shared and specific alterations occurred in community-acquired pneumonia and ctd - ild patients , which were associated with inflammatory and immune reactions , which may provide a new direction for future studies aiming to elucidate the mechanism , improve the diagnosis , and develop therapies for different respiratory diseases . as a heterogeneous and wide inflammation ,': 1, 'antibiotic': 1, 'osteoarticular': 1, 'complexation': 1, 'ropivacaine': 1, 'sufentanil': 1, 'propofol': 1, 'analgesics': 1, 'il-7': 1, 'metabolite taurine': 1, 'erysipelotrichaceae': 2, 'taurine': 1, 'betaine': 1, 'colchicine': 10, 'keratinocytes': 1, 'trehangelins': 1, 'plasma': 1, 'rituximab': 1, 'folic acid - aki )': 1, 'folic acid - aki but did not prevent kidney failure': 1, 'folic acid - aki': 1, 'vasoactive medications': 1, 'norepinephrine': 4, 'hypochlorous acid': 1, 'dimethyl fumarate ( dimethyl fumarate': 1, 'glatiramer acetate': 1, 'dimethyl fumarate': 9, 'microglial': 1, 'intraarticular': 1, 'antiinflammatory': 2, 'chondroprotective': 2, 'ccr4 antagonist': 1, 'rhinosinusitis': 1, 'bionorica': 1, 'ibuprofen': 2, 'leukotriene': 1, 'zymozan': 1, 'bno': 1, 'metagenomic': 1, 'metaproteomic': 1, 'blautia': 1, 'haematological': 1, 'pbs+aa': 2, 'phosphate - buffered saline ( phosphate-buffered saline ) liposomes': 1, 'epo': 1, 'iron': 1, 'erythropoietin': 1, 'anagliptin': 1, 'nitric oxide ( nitric oxide': 1, 'trehalose': 1, 'atherogenesis': 1, 'curcumin nanoparticles ( curcumin - nanoparticles ) against copper oxide nanoparticle ( cuo - np)-mediated hepatorenal effects on behavioral performance , biochemical markers , antioxidants , inflammation , apoptosis , and histopathology in rats . study design : twenty wistar adult male rats were randomly divided into four groups ( n=5 )': 1, 'iotaiota': 1, 'gavaged': 1, 'curcumin - nanoparticles (': 1, 'curcumin - nanoparticles': 1, 'histopathological': 2, 'uric acid': 1}, 'cancers': {'chemotherapy': 28, 'histone deacetylase': 1, 'human histone deacetylase': 1, 'histone': 4, 'deacetylase': 1, 'paeoniaceae': 1, 'cytotoxic': 1, 'antimalarials': 1, 'phosphodiesterase-5 inhibitors': 1, 'neoadjuvant immunotherapy': 1, 'nivolumab': 6, 'ipilimumab': 1, 'indole alkaloids': 1, 'diketopiperazines': 1, 'sargachromenol': 1, 'chemoradiation': 2, 'arsenic trioxide': 2, 'retinoic acid': 2, 'arsenic trioxide combined': 1, 'anthracycline': 2, 'd1': 1, 'd18': 1, 'ductal': 2, 'acinar': 1, 'clonally': 1, 'fasting insulin': 2, 'estradiol': 5, 'insulin': 4, 'paclitaxel': 5, 'heterotypic': 1, 'cox-2': 1, 'microsomal prostaglandin e': 1, 'ptges': 3, 'azoxymethane': 1, 'dextran sodium sulfate': 1, 'mpges-1': 2, 'splc': 1, 'interferon': 1, 'nomogram': 2, 'krippendorff alpha': 2, 'analgesic': 3, 'diclofenac': 7, 'opioid': 1, 'tramadol': 4, 'pain medication': 1, 'cisplatin': 9, 'docetaxel': 1, 'etoposide': 1, 'crispr': 2, 'antifungal': 2, 'anticancer': 2, 'anesthesia': 3, 'cnki': 1, 'wanfang': 1, 'anesthetics': 1, 'progesterone receptor (pr ( progesterone receptor )': 1, 'estrogen receptor': 1, 'unresectable': 1, 'nac': 1, 'braf inhibitors': 2, 'vitamin d supplementation': 1, 'cholesterol biosynthesis': 1, 'epoxidase inhibitors': 1, 'shokat': 1, 'braf': 5, 'her3': 1, 'human monoclonal antibody': 1, 'vemurafenib': 1, 'gamma)153sm': 1, 'physicochemical': 1, 'chemotherapy(tc)and': 1, 'chemo': 9, 'anastrozole': 1, 'bevacizumab': 4, 'fulvestrant)was': 1, 'glucocorticoid': 1, 'trastuzumab': 1, 'immunoblotting': 1, 'intrapleurally': 1, 'cholangiocarcinoma': 1, 'radioactive iodine ( radioiodine ) treatment increased markedly . radioiodine has been associated with an increased risk of leukemia , but risks of second solid malignancies remain unclear . we aimed to quantify risks of second malignancies associated with radioiodine treatment': 1, 'nonsignificantly': 1, 'carboplatin': 3, 'doxorubicin': 1, 'cyclophosphamide': 1, 'nanotherapeutics': 1, 'folate receptor': 1, 'folic acid': 1, 'intratumoral': 1, 'flot': 4, 'steroid': 1, 'thrombospondin': 4, 'radiosensitivity': 1, 'regulate thrombospondin': 1, 'rmats': 1, 'leafcutter': 1, 'ccl8': 1, 'ccl19': 1, 'nucleophosmin': 1, 'homodimerization': 1, 'cochrane databases': 1, 'tsrna': 1, 'cdk4': 1, 'bortezomib': 2, 'biocompatible sodium alginate': 1, 'finland': 1, 'anticoagulation': 3, 'splanchnic': 1, 'isoleucine': 2, 'embase': 1, 'medline': 1, 'superoxide anions ( o2(- )': 1, 'allosteric inhibitor': 1, 'dermatomyositis': 1, 'autoantibody': 1, 'amino acids': 1, 'fisetin': 1, 'curcumin': 1, 'luteolin': 1, 'garcinol': 1, 'probiotics': 1, 'immunohistochemistry': 1, 'itpkb': 2, 'histone deacetylase ( histone deacetylase': 1, 'proteasome inhibitors': 1, 'histone deacetylase inhibitor': 2, 'proteasome inhibitor': 2, 'ixazomib': 1, 'histone deacetylase inhibitor romidepsin synergistically induce cell': 1}, 'colorectal cancer': {'chemotherapy': 53, 'propofol': 7, 'sevoflurane': 2, 'anesthesia': 2, 'multitesting': 1, 'nctn': 1, 'indole alkaloids': 1, 'diketopiperazines': 1, 'irinotecan': 4, 'conatumumab': 1, 'quercetin': 1, 'fasting insulin': 4, 'fasting insulin ( n = 34 )': 1, 'circulating insulin': 1, 'intratumoral': 2, 'estradiol': 6, 'insulin': 5, 'mir-155_5p': 1, 'ppi': 1, 'nomogram': 3, 'ketamine': 1, 'cox-2': 1, 'microsomal prostaglandin e': 1, 'ptges': 3, 'azoxymethane': 1, 'dextran sodium sulfate': 1, 'mpges-1': 2, 'tatme.linoleic acid ( tatme.linoleic acid )': 1, 'tatme.linoleic acid': 1, 'tatme.linoleic acid treatment': 1, 'tatme.linoleic acid reduced gli2 ubiquitination': 1, 'tatme.linoleic acid - induced cleaved gli2': 1, 'tatme.linoleic acid - mediated suppression of sox17 expression . these results suggest that tatme.linoleic acid promotes tumor cell stemness': 1, 'gli2 fragments via': 1, 'gli2': 2, 'tatme.linoleic acid -': 1, 'antifungal': 1, 'anticancer': 2, 'scfas': 1, 'fluorouracil': 2, 'chemo': 2, 'anticoagulant': 1, 'warfarin': 1, 'sox': 2, 'bevacizumab': 5, 'iris': 1, 'folfiri': 1, 'australasia': 1, 'honokiol': 1, 'lidocaine': 8, 'gemcitabine': 1, 'cisplatin': 1, 'chemotherapy(act)in': 1, 'oxaliplatin': 9, 'analgesia': 8, 'laparotomies': 1, 'interquartile': 1, 'anticoagulants': 1, 'euroqol': 1, 'selenium': 1, 'panitumumab': 1, 'erlotinib': 1, 'gefitinib': 1, 'cellseg': 1, 'ccr6': 1, 'anthraquinone laxatives': 2, 'laxatives': 1, 'wnt ligands': 1, 'porcn inhibitor': 1, '23/174': 1, 'probiotics': 1, 'dihydroartemisinin': 4, 'circrna': 2, 'cochrane library databases': 1, 'nonpharmacologic': 2, 'mesalamine': 2, 'embase': 1, 'cinahl': 1, 'curcumin': 4, 'methotrexate': 5, 'fatty acid synthase ( fatty acid synthase )': 1, 'pelareorep': 1, 'oncolytic': 1, 'reovirus': 1, 'neoadjuvant chemotherapy ( neoadjuvant chemotherapy': 1, 'neoadjuvant chemotherapy': 1, 'overexpression': 1, 'cetuximab': 6, 'transwell': 1, 'bile acid receptor tgr5': 1, 'doublet chemotherapy': 3, 'doublet chemotherapy + anti - epidermal growth factor receptor ( vs doublet chemotherapy': 1, 'aom': 1, 'amino acid': 1, 'doublet chemotherapy immunotherapywith': 1, "peyer 's patches ( peyer's patches": 1, 'tlr6': 1, 'nhsii': 1, 'estrogens': 2, 'atcc': 1, 'beta inhibitors': 1, 'znf384 knockdown models were established in colorectal cancers cells': 1, 'cancerassociated': 2, 'lactic acid efflux': 1, 'antibiotic': 6, 'ancova': 1, 'carcinoembryonic': 1, 'brivanib': 1, 'axitinib': 1, 'glutamine': 1, 'gls': 1, 'jmjd2d inhibitor': 1, 'glucosamine': 3, 'influencers': 1, 'alvoxal': 2, 'lactic acid efflux inhibition': 1, 'mitoxantrone': 2, 'doxorubicin': 2, 'rhodamine': 1, 'pd-1 inhibitors': 1, 'neurotoxin rotenone': 1}, 'nact': {'chemotherapy': 298, 'neoadjuvant chemotherapy ( neoadjuvant chemotherapy': 43, 'neoadjuvant chemotherapy': 175, 'chemoradiation': 17, 'cisplatin': 38, 'paclitaxel': 36, 'docetaxel': 19, 'carboplatin': 32, 'neo': 9, 'chemo': 7, 'trastuzumab': 14, 'anthracycline': 8, 'progesterone receptors (pr ( pathological response )': 1, 'platinum compounds': 1, 'neoadjuvant chemotherapy ( docetaxel ,': 1, 'fluorouracil': 1, 'wilcoxon': 1, '8.7%]and': 1, 'ductal': 1, 'immunohistochemical': 1, 'epirubicin': 12, 'cyclophosphamide': 14, 'doxorubicin': 14, 'neoadjuvant chemotherapy ( group a )': 1, 'neoadjuvant chemotherapy ( group b )': 1, 'neoadjuvant chemotherapy ( group c )': 1, 'trachelectomy': 4, 'neoadjuvant chemotherapy - concurrent chemoradiation': 1, 'loplatin': 2, 'akaike': 1, 'nomogram': 1, '01/01/2003': 1, 'pfs': 2, 'peg - filgrastim was prophylactically administered': 1, 'oligometastatic': 1, 'nomograms': 1, 'neoadjuvant': 1, 'autophagy': 1, 'scopus': 1, 'extracellular citrate': 1, 'etoposide': 1, 'teleconsultation': 1, 'neoadjuvant chemotherapy protocols implemented': 1, 'uft': 1, 'estrogen receptors': 1, 'citrate transporter ( nact )': 2, 'citrate': 1, 'exogenous citrate': 1, 'citrate supplementation increases de novo lipogenesis and (delta- growth of hepatocellular carcinoma cells': 1, 'citrate supplementation rescues huh7 cell (ic viability in response to glutamine deprivation or zn(2 + ) treatment , and (delta- nact deficiency mitigates these effects . collectively , these findings demonstrate that nact - mediated citrate uptake': 1, 'bevacizumab': 7, 'formalin': 1, 'mucinous': 1, 'chemoradiotherapy': 2, 'nact+ccrt': 2, 'chemotherapeutics': 1, 'gemcitabine': 3, 'blue dye': 1, 'progesterone receptor (pr ( pathological response )': 1, 'infusional': 1, 'methotrexate': 1, 'divalent anion sodium symporter ( divalent anion sodium symporter': 1, 'antibiotic': 1, 'anion sodium symporter': 1, 'dicarboxylate transporter': 1, 'divalent anion sodium symporter protein structures': 1, 'divalent anion sodium symporter proteins': 1, 'ethyl sulfate': 1, 'oxaliplatin': 8, 'albumin': 1, 'adjuvant chemotherapy': 1, 'anthracyclines': 4, 'anticoagulation': 2, 'methylene blue dye': 1, 'ifosfamide': 1, 'heparin': 1, 'nact+ids': 1, 'adnexa': 1, 'pertuzumab': 1, 'embase': 1, 'nagelkerke': 1, 'cdk inhibitors': 1, 'convolutional': 1, 'analgesia': 1, 'porphyromonas': 3, 'postmastectomy': 1, 'nact.background': 1, 'sodium citrate ( nact )': 1, 'nact': 1, '46,274': 1, 'emtansine': 1, 'rishikesh': 2, 'sonomammography': 1, 'neoadjuvant chemotherapy containing anti - human epidermal growth factor receptor 2 reagent': 1, 'nucleic acid sampling (': 1, 'nucleic acid sampling following neoadjuvant': 1, 'nucleic acid sampling': 1, 'neoadjuvant chemotherapy - interval debulking': 1}}
